Roche. Q1 2016 sales. Basel, 19 April 2016

Roche Q1 2016 sales Basel, 19 April 2016

This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates, future or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected. 3

Group Severin Schwan Chief Executive Officer 4

Q1 2016: Good start to the year Growth Sales Group sales +4% 1 driven by HER2 franchise (+9%), Immunology franchise (+16%), Avastin (+4%), and Professional Diagnostics (+7%) Good growth 1 in all regions: US (+3%), Europe (+3%), Japan (+3%) and International (+7%) Innovation Oncology Neuroscience Diagnostics Atezolizumab: Acceptance of filing for advanced bladder and lung cancer in the US Successful US launches of Alecensa and Cotellic US approval of Gazyva in R/R NHL (GADOLIN) US approval of Venclexta (venetoclax) in R/R CLL 17p deletion Ocrevus (ocrelizumab): Updated NEDA and MRI data at AAN (April, 15 th 21 st ) IND approval to initiate Zika blood screening 1 At constant exchange rates (CER); NEDA=no evidence of disease activity; MRI=magnetic resonance imaging; IND: Investigational New Drug Application 5

Q1 2016: Solid sales growth continues 2016 2015 Change in % CHFbn CHFbn CHF CER Pharmaceuticals Division 9.8 9.3 5 4 Diagnostics Division 2.6 2.5 4 5 Roche Group 12.4 11.8 5 4 CER=Constant Exchange Rates 6

Q1 2016: Sales growth for fifth consecutive year 10% 8% 6% 6% 6% 6% 8% 7% 5% 5% 6% 7% 6% 4% 4% 4% 4% 5% 4% 4% 2% 2% 0% Q1 12 Q2 12 Q3 12 Q4 12 Q1 13 Q2 13 Q3 13 Q4 13 Q1 14 Q2 14 Q3 14 Q4 14 Q1 15 Q2 15 Q3 15 Q4 15 Q1 16 All growth rates at Constant Exchange Rates (CER) 7

Q1 2016: Solid sales growth in all regions CHFbn 6 5 +3% 0% 4 3 2 1 0 +3% +7% -1% +16% +3% +3% -3% +4% +5% +4% Japan International Europe US Diagnostics Pharma All growth rates at Constant Exchange Rates (CER) 8

Roche significantly advancing patient care Recognition for innovation 2013-present 12 Breakthrough Therapy Designations Rank Company # 1 Roche 12 2 BMS 8 3 Novartis 7 3 Merck 6 3 Pfizer 6 4 GSK 5 Year 2016 2015 2014 2013 Molecule Ocrelizumab (PPMS) Venclexta (AML) Venclexta + Rituxan (R/R CLL) Actemra (Systemic sclerosis) Atezolizumab (NSCLC) Venclexta (R/R CLL 17p del) Emicizumab/ACE 910 (Hemophilia A) Esbriet (IPF) Lucentis (DR) Atezolizumab (Bladder) Alectinib (2L ALK+ NSCLC) Gazyva (1L CLL) Source: http://www.focr.org/breakthrough-therapies as at 22 March 2016; PPMS=Primary Progressive Multiple Sclerosis; CLL=Chronic Lymphocytic Leukemia; NSCLC=Non-Small Cell Lung Cancer; IPF=Idiopathic Pulmonary Hypertension; DR=Diabetic Retinopathy 9

Significant launch activities ahead 2016 2017 2018 Venclexta R/R CLL with 17p del Emicizumab (ACE910) Hemophilia A Lampalizumab Geographic atrophy Cotellic + Zelboraf BRAFmut melanoma Lebrikizumab Severe Asthma Atezolizumab+Avastin+chemo 1L NSCLC Pharma Alecensa 2L ALK+ NSCLC Atezolizumab 2L+ lung and bladder cancer Ocrelizumab RMS/ PPMS Perjeta + Herceptin ebc HER2+ (APHINITY) Atezolizumab + Avastin 1L RCC Gazyva 1L inhl (GALLIUM) Gazyva Refractory inhl (GADOLIN) Gazyva 1L anhl (GOYA) Alecensa 1L ALK+ NSCLC Actemra Giant cell arteritis Diagnostics cobas e 801 launch in immunodiagnostics cobas t 511 cobas t 711 cobas 6000 (new) Oncology/ hematology Neuroscience Ophthalmology Immunology FDA Breakthrough Therapy Designation Outcome studies are event-driven: timelines may change. Standard approval timelines of 1 year assumed. 10

2016 outlook Group sales growth 1 Low to mid-single digit Core EPS growth 1 Ahead of sales growth Dividend outlook Further increase dividend in Swiss francs 1 At Constant Exchange Rates (CER) 11

Pharmaceuticals Division Daniel O Day COO Roche Pharmaceuticals 12

Q1 2016 sales Innovation Outlook 13

Q1 2016: Pharma sales Good growth driven by all regions 2016 2015 Change in % CHFm CHFm CHF CER Pharmaceuticals Division 9,800 9,322 5 4 United States 4,716 4,392 7 3 Europe 2,319 2,178 6 5 Japan 853 763 12 4 International 1,912 1,989-4 4 CER=Constant Exchange Rates 14

Q1 2016: Oncology and immunology driving growth Perjeta +33% Esbriet +96% Herceptin +4% Avastin +4% Xolair +22% MabThera/Rituxan +3% Actemra/RoActemra +14% Activase/TNKase +21% Tamiflu -6% Tarceva Lucentis Pegasys -50% -13% -14% US Europe Japan International -120-60 0 60 120 CHFm Absolute values and growth rates at Constant Exchange Rates (CER) 15

Q1 2016: Oncology launches off to a good start HER2 Avastin Perjeta Herceptin +9% +4% YoY CER growth Kadcyla Strong uptake of Perjeta and Kadcyla Growth of Herceptin due to longer treatment Growth driven mainly by cervical and ovarian CD20 MabThera/Rituxan (Oncology) +3% Gazyva approved in R/R inhl (GADOLIN) Tarceva -14% Gazyva/Gazyvaro Increased competition EU: Avastin + Tarceva filed in 1L EGFR+ NSCLC Xeloda -17% Loss of exclusivity Zelboraf + Cotellic Cotellic +18% Back to growth post launch of Cotellic Alecensa +161% US: launch off to a strong start Japan: Continued strong growth (J-ALEX study) CHFbn 0 1 2 3 CER=Constant Exchange Rates Q1 2016 Oncology sales: CHF 6.1bn; CER growth +4% 16

HER2 franchise: Growth mainly driven by Perjeta CHFm 2,500 2,000 1,500 +15% +17% +23% YoY CER growth +9% HER2 franchise Q1 2016 Herceptin (+4%): Longer treatment duration in combo with Perjeta Perjeta (+33%): Strong demand in 1L mbc and neoadjuvant in the US and EU Kadcyla (+11%): Growth driven by EU, International and Japan 1,000 500 0 Q1 13 Q1 14 Q1 15 Q1 16 Herceptin Perjeta Kadcyla Outlook 2016 Herceptin: Further SC conversion Perjeta: Further increasing penetration Kadcyla: New launch countries Ph III APHINITY data (adj. HER2+) expected CER=Constant Exchange Rates 17

Avastin: Strong underlying growth CHFm 2,000 YoY CER growth Avastin Q1 2016 1,600 1,200 +11% +9% +6% +4% Growth impacted by Health Insurance Plan impact in Japan International (+27%): Driven by Asia, mainly China (lung cancer launch) 800 Outlook 2016 400 0 Q1 13 Q1 14 Q1 15 Q1 16 US Europe International Japan Continued uptake in ovarian and cervical EU: Avastin + Tarceva approval in EGFR+ NSCLC expected in H2 CER=Constant Exchange Rates 18

Immunology: Continued strong growth, now >CHF 7bn on an annualised basis CHFm 1,800 1,500 1,200 +11% +11% +20% YoY CER growth +16% Immunology Q1 2016 Xolair (+22%) Continued strong uptake in allergic asthma, chronic idiopathic urticaria Actemra (+14%) 900 SC formulation driving growth 600 Increasing 1L monotherapy leadership focusing on MTX intolerant patients 300 MabThera/Rituxan (+11%) 0 Q1 Q1 13 14 MabThera/Rituxan (RA) Actemra SC CellCept Esbriet Q1 15 Actemra IV Xolair Pulmozyme Other CER=Constant Exchange Rates; GPA=granulomatosis with polyangiitis; MPA=microscopic polyangiitis Q1 16 Continues to grow in rheumatoid arthritis and vasculitis (GPA and MPA) 19

Esbriet: Expanding beyond severe patients CHFm 200 150 YoY CER growth +96% 178 US (+145%) Strong underlying growth with patient starts and treatment rate on track Around 100,000 IPF patients in the US with high unmet need 100 50 0 10 Q1 13 27 Q1 14 88 Q1 15 US Europe International Q1 16 EU (+36%) Increasing differentiation due to strengthened label including the pooled 1 Yr mortality data Outlook 2016 Increasing patient pool and new launch countries 20

Q1 2016 sales Innovation Outlook 21

Venclexta* in R/R CLL with 17p deletion First Bcl-2 inhibitor with significant upside potential Phase II (M13-982) Response, n (%) Venclexta (n = 106) ORR 85 (80.2) CR/CRi 8 (7.5) Median DOR not reached Accelerated approval in the US following breakthrough therapy designation in R/R CLL 17p del Additional breakthrough therapy designations: Venclexta+Rituxan in R/R CLL and Venclexta in AML Several read-outs at ASCO in NHL, CLL, MM and AML NHL=non-hodgkin`s lymphoma; CLL=chronic lymphoid leukemia; MM=multiple myeloma; AML=acute myeloid leukemia; * Venclexta (venetoclax) in collaboration with AbbVie 22

Ocrelizumab: Additional efficacy data at AAN Breakthrough therapy designation in PPMS NEDA, disability progression and MRI data to be presented at AAN (April, 15 th 21 st ) Breakthrough therapy designation granted in PPMS US/EU filings in RMS/PPMS on track for H1 2016 NEDA=no evidence of disease activity; MRI=magnetic resonance imaging 23

Emicizumab (ACE 910) development plan Non-interventional study expanded to all patients Inhibitor study: Enrollment progressing well Inhibitor non-interventional study fully recruited (>90 patients) and expanded to non-inhibitors Non-inhibitor, pediatric and Q4W dosing studies expected to start in 2016 QW=weekly dosing; Q2W=dosing every 2 weeks; Q4W=dosing every 4 weeks; OLE=open label extension 24

Unlocking the full value of cancer immunotherapy New deals signed in Q1 Priming & activation anti-cea-il2v FP (cergutuzumab amunaleukin) anti-fap-il2v FP anti-ox40 anti-cd27* (Celldex) entinostat* (Syndax) T cell Trafficking T cell infiltration anti-vegf (Avastin) anti-ang2/vegf (vanucizumab) Antigen presentation T-Vec oncolytic virus* (Amgen) INFa anti-cd40 CMB305 vaccine* (Immune Design) Cancer T cell recognition anti-cea/cd3 TCB anti-cd20/cd3 TCB KTE-C19* (Kite Pharma) ImmTAC* (Immunocore) Clinical development Preclinical development Established therapies In-house CIT NMEs in the clinic * Partnered or external Antigen release EGFRi (Tarceva) ALKi (Alecensa) BRAFi (Zelboraf) MEKi (Cotellic) anti-cd20 (Gazyva) anti-her2 (Herceptin; Kadcyla; Perjeta) various chemotherapies lenalidomide* (Celgene) rociletinib* (Clovis) daratumumab* (Janssen) T cell killing anti-pdl1 (atezolizumab) anti-csf-1r (emactuzumab) IDOi (NewLink) IDOi* (Incyte) CPI-444* (Corvus) anti-tigit IDO1/TDOi* (Curadev) Chen and Mellman. Immunity 2013 NME=new molecular entity; CIT=cancer immunotherapy; FP=fusion protein; TCB=T-cell bispecific 25

Cancer immunotherapy read-outs in 2016 Priority review granted for bladder and lung cancer atezo+chemo Solid tumors atezo+cotellic Solid tumors atezo+avastin+/-chemo Solid tumors acea-il2v FP Solid tumors aox40 Solid tumors acea/cd3 TCB Solid tumors atezo+ido Solid tumors atezo+aox40 Solid tumors atezo Solid tumors atezo+acd40 Solid tumors atezo+ifn-alfa Solid tumors afap-il2v FP Solid tumors atezo+ipilimumab Solid tumors Phase I IDO Solid tumors atezo+acea/cd3 TCB Solid tumors atezo+acsf-1r Solid tumors atezo+acea-il2v FP Solid tumors acsf-1r Solid tumors atezo+zelboraf+cotellic Melanoma atezo+zelboraf Melanoma atezo+tarceva NSCLC atezo+alecensa ALK+ NSCLC atezo+kadcyla/herceptin+perjeta HER2+ ebc/mbc atezo+gazyva R/R FL / anhl atezo+gazyva+lenalidomide R/R FL/aNHL acd40+vanucizumab R/R FL/aNHL Status as of April 19, 2016; Outcome studies are event-driven: timelines may change. atezo+daratumumab+len R/R MM atezo+lenalidomide MM atezo+gazyva+polatuzumab R/R FL/aNHL atezo+gazyva+chemo R/R FL/aNHL acd20/cd3 TCB heme tumors atezo+/-azacitidine MDS Phase II atezo NSCLC (Dx+) (BIRCH) atezo 2/3L NSCLC (POPLAR) atezo 1/2L Bladder (IMvigor 210) atezo+avastin 1L Renal (IMmotion 150) = Read-outs expected in 2016 Phase III atezo 2/3L NSCLC (OAK) atezo+avastin+chemo 1L nsq NSCLC (IMpower 150) atezo+chemo 1L nsq NSCLC (IMpower 130) atezo+chemo 1L nsq NSCLC (IMpower 132) atezo 1L nsq NSCLC (Dx+) (IMpower 110) atezo 1L sq NSCLC (Dx+) (IMpower 111) atezo+chemo 1L sq NSCLC (IMpower 131) atezo Adj NSCLC (Dx+) (IMpower 010) atezo 2/3L Bladder (IMvigor 211) atezo Adj MIBC (Dx+) (IMvigor 010) atezo+chemo 1L TNBC (IMpassion 130) atezo+avastin 1L Renal (IMmotion 151) 26

Q1 2016 sales Innovation Outlook 27

2016: Focus on ongoing and upcoming launches Approvals & launch preparation Ocrevus (ocrelizumab) in MS Atezolizumab in bladder and lung cancer Gazyva (GOYA) and Perjeta (APHINITY) Maximise recent launches Venclexta (venetoclax) in R/R CLL with 17p deletion Alecensa in ALK positive NSCLC Cotellic + Zelboraf in 1L BRAF positive metastatic melanoma Gazyva in Rituxan-refractory inhl (GADOLIN) * Outcome studies are event driven, timelines may change 28

line extensions NMEs 2016 onwards: Significant launch activities Venclexta R/R CLL with 17p del Cotellic + Zelboraf BRAFmut melanoma Emicizumab (ACE910) Hemophilia A Alecensa 2L ALK+ NSCLC Atezolizumab 2L+ lung and bladder cancer Lebrikizumab Severe Asthma Ocrelizumab RMS/ PPMS Lampalizumab Geographic atrophy 2016 2017 2018 Gazyva Refractory inhl (GADOLIN) Perjeta + Herceptin ebc HER2+ (APHINITY) Atezolizumab+Avastin+chemo 1L NSCLC Gazyva 1L anhl (GOYA) Actemra Giant cell arteritis Atezolizumab + Avastin 1L RCC Gazyva 1L inhl (GALLIUM) Alecensa 1L ALK+ NSCLC Oncology/ hematology Neuroscience Ophthalmology Immunology Outcome studies are event-driven: timelines may change. Standard approval timelines of 1 year assumed. FDA Breakthrough Therapy Designation 29

ASCO 2016: Highlights in various cancer types Solid tumors atezolizumab + aox40: Ph I atezolizumab + Cotellic: Ph I in CRC Lung Alecensa: Ph III (J-ALEX) in 1L ALK+ NSCLC atezolizumab: Ph II OS update (POPLAR) in 2/3L NSCLC Bladder atezolizumab: Ph II (IMvigor210) 1L cohort and 2L cohort update in bladder Breast Herceptin + Perjeta: Ph III (PHEREXA) in 2L HER2+ mbc atezolizumab + abraxane: Ph I update in TNBC Hematology Venclexta: Ph II (CAVALLI) in 1L anhl Venclexta: Ph I in R/R CLL and R/R NHL Venclexta +/- chemo: Ph I in R/R MM Venclexta + chemo: Ph I in AML Cotellic in collaboration with Exelixis; Alecensa in collaboration with Chugai; Gazyva in collaboration with Biogen Idec 30

Additional key oncology presentations in 2016* New Orleans, 16-20 Apr EHA Copenhagen, 9-12 Jun aox40: Ph I dose escalation in solid tumors atezoliztumab + Avastin + FOLFOX: Ph I in CRC atezolizumab + Gazyva: Ph I in R/R anhl/inhl idasanutlin + AraC: Ph I in R/R AML Copenhagen, 7-11 Oct atezolizumab + abraxane: Ph I in TNBC atezolizumab + IDOi: Ph I atezolizumab + Zelboraf + Cotellic: Ph1 in 1L BRAF+ mm atezolizumab: Ph II (IMvigor 210) in bladder atezolizumab: Ph I in SCLC atezolizumab: Ph III (OAK) in 2L NSCLC [or IASLC Vienna] San Diego, 3-6 Dec atezolizumab + lenalidomide: Ph I in MM (safety) atezoliztumab + azacytidine: Ph I in MDS (safety) acd20/cd3 TCB: Ph I dose escalation in solid tumors Gazyva: Ph III (GOYA) in front-line anhl polatuzumab + Gazyva/Rituxan: Ph II (ROMULUS) in R/R FL / anhl polatuzumab + Gazyva/Rituxan + CHP: Ph I/II in 1L anhl polatuzumab + Gazyva: Ph I/II in 1L anhl and R/R FL Venclexta + Rituxan +/- bedamustin: Ph II (CONTRALTO) in R/R FL Venclexta + Gazyva or +Rituxan +/- benda: Ph I in R/R CLL Venclexta: Ph II in ibrutinib/idelalisib ref R/R CLL atezolizumab: Ph III (OAK) in 2L NSCLC atezoliztumab + Tarceva: Ph I in NSCLC Vienna, 4-7 Dec San Antonio, 6-10 Dec atezolizumab + abraxane: Ph I update in TNBC taselisib: Ph II (LORELEI) in neoadjuvant HER2-/ER+ BC SERD: Ph II * Planned submissions (to be confirmed); Outcome studies are event driven, timelines may change 31

2016: Key late-stage news flow Regulatory Phase III readouts* Phase II readouts* Compound Indication Milestone Gazyva Rituxan-refractory inhl US/EU approval Venclexta R/R CLL with 17p deletion US approval ocrelizumab RMS/PPMS US/EU filing atezolizumab Bladder cancer US approval atezolizumab 2/3L NSCLC US approval Alecensa 2L ALK+ NSCLC EU CHMP opinion lebrikizumab Severe asthma Ph III LAVOLTA I/II atezolizumab 2/3L NSCLC Ph III OAK Gazyva Front-line anhl Ph III GOYA Perjeta + Herceptin Adjuvant HER2+ BC Ph III APHINITY Actemra Giant cell arthritis Ph III GiACTA Alecensa 1L ALK+ NSCLC Ph III ALEX lebrikizumab Atopic dermatitis Ph II TREBLE, ARBAN atezolizumab Bladder cancer Ph II IMvigor 210 (1L cohort) atezolizumab + Avastin 1L Renal cancer Ph II IMmotion 150 Venclexta + Rituxan R/R FL (inhl) Ph II CONTRALTO Venclexta + Rituxan/Gazyva 1L anhl Ph II CAVALLI mixed * Outcome studies are event driven, timelines may change 32

Diagnostics Division Roland Diggelmann COO Roche Diagnostics 33

Q1 2016: Diagnostics Division sales Strong sales growth in laboratory businesses 2016 2015 Change in % CHFm CHFm CHF CER Diagnostics Division 2,614 2,511 4 5 Professional Diagnostics 1,519 1,425 7 7 Molecular Diagnostics 446 401 11 11 Diabetes Care 443 507-13 -11 Tissue Diagnostics 206 178 16 13 CER=Constant Exchange Rates; Underlying growth of Molecular Diagnostics excluding Sequencing business: +4% 34

Q1 2016: Diagnostics regional sales Growth driven by Asia Pacific and Latin America North America 0% 27% of divisional sales EMEA 1 +1% 43% of divisional sales Japan -3% 4% of divisional sales Latin America +21% 6% of divisional sales Asia Pacific +16% 20% of divisional sales 23% growth in E7 countries 2 1 Europe, Middle East and Africa; 2 Brazil, China, India, Mexico, Russia, South Korea, Turkey All growth rates at Constant Exchange Rates 35

Q1 2016: Diagnostics highlights Growth driven by Professional Diagnostics YoY CER growth Professional Dia +7% Driven by immunodiagnostics (+12%) Molecular 1 Dia +11% Virology (+16%) incl. HPV (+16%) Diabetes Care -11% Spillover of US reimbursement cuts to private sector Tissue Dia +13% EMEA North America RoW Advanced staining portfolio (+10%); primary staining (+24%) CHFbn 0.0 0.5 1.0 1.5 2.0 1 Underlying growth of Molecular Diagnostics excluding sequencing business: +4% CER=Constant Exchange Rates; EMEA=Europe, Middle East and Africa 36

Providing the full solution in hepatitis testing Comprehensive menu in serology & molecular Complete platform and test portfolio Hepatitis contributes ~60% of Roche s Infectious Disease/Virology portfolio Serology hepatitis: (+5% 1 ) Molecular/NAT* hepatitis: (+11% 1 ) Leader in a CHF 4.3bn market 5yr CAGR: ~6% projected Strong growth potential in serology Roche 25% Others 75% 1 Q1 2016 growth; *NAT: nucleic acid amplification technology 37

FDA approves IND for cobas Zika assay Screening initiated at Puerto Rico blood centres Currently testing in Puerto Rico, expect to expand into southern US centres Operating under an IND* cost-recovery model, no commercial sales * IND: Investigational New Drug Application 38

Key launches 2016 Instruments / Devices Tests / Assays Area Product Market Central Laboratory cobas 8000 <e 801> high throughput immunochemistry analyzer cobas c 513 high throughput dedicated HbA1c analyzer Point of Care CoaguChek INRange (Zenith) modified analyzer for intuitive self testing with full blue tooth connectivity Sequencing Diabetes Care Roche SMRT Sequencer single molecule sequencer for clinical research (in collaboration with Pacific Biosciences) Accu-Chek Guide next-generation blood glucose monitoring system Accu-Chek Insight CGM new high-performance continuous glucose monitoring system Virology cobas 6800/8800 HIV Qual early Infant Diagnosis and Confirmatory HIV Test EU HPV / Microbiology Point of Care Sequencing Companion Diagnostics cobas 6800/8800 CT/NG fully automated solution for screening and diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae in symptomatic & asymptomatic patients cobas Liat Influenza A/B plus RSV (CLIA) automated multiplex real time RT-PCR assay for qualitative detection and discrimination of Influenza A virus, Influenza B virus and respiratory syncytial virus (RSV) ctdna oncology panels liquid biopsy for circulating tumor DNA for cancer therapy selection PD-L1 (SP142) for Bladder Cancer* companion diagnostic for atezolizumab PD-L1 (SP142) for NSCLC* companion diagnostic for atezolizumab EU US EU WW EU EU EU US US US US * achieve commercial readiness, dependent on Pharma label and approval 39

Finance Alan Hippe Chief Financial Officer 40

Q1 2016: Highlights Sales Good sales growth in all regions and both divisions Guidance for FY 2016 2015 core EPS base for CER calculation: CHF 13.85 Currency impact Positive impact from USD, JPY and EUR currencies partly offset by Latin America Capital markets update Bond maturity EUR: 2.1bn maturity on 4 March 2016 - coupon 5.625% Bond tender USD: 0.6bn (0.86bn outstanding, maturity in 2019) coupon 6.0% s.a. Bond issuance EUR: 0.65bn maturity in 2023 - coupon 0.5% USD: 1.0bn maturity in 2026 - coupon 2.625% s.a. s.a.=semi-annual coupon 41

Q1 2016: Group sales Increase driven by US & EU Pharma and Diagnostics +3% +5% +4% +4% +5% +4% +5% Pharma Division +4% +115 +124 +133 +107 +72 +30 +457 +581 United States Europe Intl. Japan Diagnostics Division Group Fx Group CHF 1 Absolute values and growth rates at Constant Exchange Rates (CER) 1 average Full Year 2015 to average Q1 2016 Fx 42

Exchange rate impact on sales growth Positive impact from USD, JPY and EUR +1.9p +0.6p +0.4p -0.2p -0.2p -0.2p -1.3p CER sales growth Q1 2016 vs. Q1 2015 +3.9% +4.9% CHF sales growth Q1 2016 vs. Q1 2015 CER USD JPY EUR Other Europe As-Pac Other Lat-Am CHF CER=Constant Exchange Rates 43

Currency impact on Swiss Franc results 2016 Low currency impact expected CHF / USD Average YTD 2015 CHF / EUR 0.99 0.98 Assumed average YTD 2016 4% 3% 2% 1% 0.97 +1% 0.95 +1% 0.95 0.95 0.97 1.01 0.99 0.98 0.97 0.97 0.97 0.97 0.97 0.97 0.97 0.97 0.97 Monthly avg fx rates 2016 Fx rates at 31 March 2016 J F M A M J J A S O N D 0.96 2% 3% 3% 2% 1.10 1.10 1.09 1.09 1.08 +2% +2% 1.06 1.06 1.07 Assuming the 31 Mar 2016 exchange rates remain stable until end of 2016, 2016 impact is expected to be (%p): Q1 HY Sep YTD FY Sales 1 1 1 0 Core operating profit 0-1 Core EPS -1 0 1.09 1.10 1.09 1.09 1.09 1.09 1.09 1.09 1.09 1.09 1.09 1.09 J F M A M J J A S O N D 44

2015: Core EPS base for FY 2016 guidance +0.36 13.85 13.49 excl. Venezuela & Argentina FX losses Core EPS Full Year 2015 as reported Core EPS Full Year 2015 @ CER 45

2016 outlook Group sales growth 1 Low to mid-single digit Core EPS growth 1 Ahead of sales growth Dividend outlook Further increase dividend in Swiss francs 1 At Constant Exchange Rates (CER) 46

2016: Upcoming IR events 5 June 21 July 2 August 20 October Analyst Event at ASCO Half Year Results Analyst Event on Diagnostics Division at AACC Third Quarter Results Further details available online: http://www.roche.com/investors/agenda.htm 47

Pipeline summary Marketed products additional indications Global Development late-stage trials pred (Roche Pharma Research & Early Development) gred (Genentech Research & Early Development) Roche Group Q1 2016 sales Diagnostics Foreign exchange rate information 48

Changes to the development pipeline Q1 2016 update New to Phase I New to Phase II New to Phase III New to Registration 1 NME transitioned from Ph0 RG7906 psychiatric disorders 1 NME re-opened in Ph1 RG7203 PDE10A inh schizophrenia 1 NME in-licensed from Amgen RG6149 ST2 MAb - asthma 1 NME acquired from Tensha RG6146 BET inh oncology (CIT) 3 new AIs RG7876 CD40+vanucizumab solid tumors RG7601 Venclexta+Cotellic/idasanutlin AML RG3616 Erivedge+ruxolitinib myelofibrosis 1 NME in-licensed from Shionogi RG6152 CAP endonuclease inh - influenza 1 NME transitioned from Ph2 RG7412 crenezumab Alzheimer s 1 AI RG7446 atezolizumab + chemotherapy + pemetrexed NSCLC non-sq. 1L 1 AI transitioned from Ph2 RG7446 atezolizumab NSCLC 2L+ Removed from Phase I Removed from Phase II Removed from Phase III Removed from Registration 2 NMEs RG7116 lumretuzumab mbc RG7597 duligotuzumab solid tumors 1 NME RG7090 basimglurant TRD (out-licensing activities ongoing) 1 NME (status assigned to Ph1) RG7155 emactuzumab PVNS tumors 1NME following FDA approval RG7601 Venclexta (venetoclax) 17pdel CLL rel/ref Status as of April 19, 2016 49

Roche Group development pipeline RG6016 RG6047 RG6061 RG6078 RG6078 RG6146 RG7155 RG7159 RG7304 RG7386 RG7446 RG7446 RG7446 RG7446 RG7446 RG7446 RG7446 RG7446 RG7446 RG7461 RG7601 RG7601 RG7601 RG7741 RG7775 RG7802 RG7813 RG7828 RG7841 RG7842 RG7876 RG7876 RG7882 RG7888 RG7888 RG7986 LSD1 inh SERD (2) HIF1 alpha LNA IDO inh IDO inh + atezolizumab BET inh Raf & MEK dual inh atezolizumab atezo+zelboraf+/-cotellic atezo+avastin+chemo atezolizumab+cotellic atezolizumab+ipi/ifn atezo+tarceva /Alecensa atezolizumab+gazyva Venclexta (venetoclax)+gazyva Phase I (43 NMEs+19 AIs) solid tumors solid tumors melanoma solid tumors solid tumors NSCLC CLL Venclexta+Cotellic/idasanutlin AML CL ChK1 inh solid tum & lymphoma MDM2 (4) IV prodrug Ly6E ADC ERK inh + Cotellic ADC OX40 MAb AML ER+(HER2-neg) mbc solid tumors solid tumors emactuzumab + atezolizumab s. tumors FAP-DR5 bimab atezo+lenalidomide/daratumumab FAP IL2v FP solid tumors lymphoma Venclexta (venetoclax) heme indications AML CEACD3 TCB ± atezolizumab s. tumors *CEA IL2v FP+atezolizumab CD20/CD3 bimab solid tumors Gazyva multiple combos heme indications atezolizumab + K/HP solid tumors MM solid tumors s. tumors heme tumors solid tumors solid tumors CD40 MAb+atezolizumab solid tumors CD40 MAb+vanucizumab solid tumors ovarian ca solid tumors OX40 MAb + atezolizumab solid tumors ADC * INN: cergutuzumab amunaleukin oncology HER2+ BC r/r NHL RG3616 RG3616 RG6069 RG6125 RG6149 RG7159 RG7625 RG7845 RG7880 RG6024 RG6080 RG7834 RG7861 RG7944 RG7992 RG6029 RG7203 RG7800 RG7893 RG7906 RG7916 RG7935 IONIS CHU RG4929 CLL Erivedge+Esbriet Erivedge+ruxolitinib - fibrosis Cadherin-11 MAb ST2 MAb obinutuzumab Cat-S antag BTK inh IL-22Fc Flu B MAb SMN2 splicer Nav1.7 inh a-synuclein MAb autoimmune diseases autoimmune diseases inflammatory diseases DBO β-lactamase inh bact. infections - HBV StaphA vcrifalog TAC therapeutic vaccine FGFR1/KLB MAb Nav1.7 inh (2) PDE10A inh ASO PTH1 recep. ago IPF RA renal transplant influenza B infect. diseases HBV metabolic diseases pain spinal muscular atrophy pain SMN2 splicer(2) spinal muscular atrophy Parkinson's Disease Huntington s Disease hypoparathyroidism PT CHU - hyperphosphatemia - glaucoma New Molecular Entity (NME) Additional Indication (AI) Oncology Immunology Infectious Diseases CardioMetabolism Neuroscience Ophthalmology Other myelofibrosis asthma schizophrenia - psychiatric disorders RG-No CHU IONIS PRO Phase II (16 NMEs+12 Als) RG3502 Kadcyla HER2+ NSCLC RG6046 SERD ER+(HER2-neg) mbc RG7221 vanucizumab mcrc RG7421 Cotellic+paclitaxel TNBC RG7440 ipatasertib solid tumors RG7596 polatuzumab vedotin heme tumors RG7601 Venclexta (venetoclax) DLBCL RG7601 Venclexta (venetoclax)+rituxan FLrel/ref RG7604 taselisib NSCLC sq 2L RG7604 taselisib ER+(HER2-neg) BC neoadj RG7686 codrituzumab hepatocell. carcinoma RG3637 lebrikizumab +/- Esbriet IPF RG3637 lebrikizumab atopic dermatitis RG3637 lebrikizumab COPD RG7159 obinutuzumab lupus nephritis CHU nemolizumab (IL-31R) atopic dermatitis CHU nemolizumab (IL-31R) pruritus dialysis pts PRO VAP-1 inh inflammatory diseases RG6152 CAP endonuclease inh influenza RG7227 danoprevir HCV RG7745 Flu A MAb influenza A RG7795 TLR7 agonist HBV CHU URAT1 inh gout RG1662 basmisanil Down s syndrome RG6083 olesoxime spinal muscular atrophy RG7314 V1 receptor antag autism RG3645 ranibizumab PDS wamd RG7716 VEGF-ANG2 bimab wamd Roche/Genentech managed Chugai managed IONIS managed Proximagen managed Status as of April 19, 2016 50

Roche Group development pipeline RG435 RG435 1 RG1273 RG1273 RG1273 RG3502 RG3502 RG7159 RG7159 RG7204 RG7601 RG7853 Avastin Perjeta+Herceptin Gazyva Zelboraf glioblastoma 1L HER2+ mbc 2L Perjeta+Herceptin HER2+ BC adj Perjeta+Herceptin HER2+gastric ca 1L Kadcyla Kadcyla + Perjeta Gazyva Alecensa (alectinib) HER2+ BC adj HER2+ BC adj DLBCL1L follicular lymphoma 1L melanoma adj Venclexta (venetoclax)+rituxancll rel/ref ALK+ NSCLC 1L Phase III (10 NMEs + 30 Als) RG1569 RG3637 RG7413 RG7413 CHU RG1450 RG1594 RG1594 RG7417 Actemra lebrikizumab etrolizumab etrolizumab Actemra gantenerumab ocrelizumab ocrelizumab lampalizumab giant cell arteritis severe asthma ulcerative colitis Crohn s disease large-vessel vasculitis RG3502 Kadcyla + Perjeta HER2+ BC neoadj CHU IL-6R MAb neuromyelitis optica RG7446 RG7446 RG7601 Avastin atezolizumab+avastin rel. ovarian ca. Pt-sensitive atezolizumab+chemo NSCLC non-sq. 1L 1L NSC RG7446 atezo+chemo+avastin NSCLC non-sq. 1L RG7446 RG7446 RG7446 RG7446 RG7446 RG7446 RG7446 RG7604 RG6013 RG7388 atezo+chemo+pemetrexed NSCLC non-sq. 1L atezolizumab+chemo atezolizumab Dx+ atezolizumab Dx+ atezolizumab Dx+ atezolizumab+abraxane Venclexta (venetoclax)+gazyva taselisib NSCLC sq. 1L NSCLC non-sq. 1L NSCLC adj TNBC RCC atezolizumab muscle inv. bladder ca adj emicizumab idasanutllin Status as of April 19, 2016 NSCLC sq. 1L CLL 1L ER+(HER2-neg) mbc hemophilia A AML RG105 RG1569 RG7412 MabThera Actemra crenezumab pemphigus vulgaris systemic sclerosis Alzheimer s RMS PPMS Alzheimer s geographic atrophy RG105 2 MabThera SC CLL RG435 3 Avastin+Tarceva EGFR mut+ NSCLC RG7159 4 RG7446 5 RG7446 5 RG7853 6 Registration (2 NMEs + 4 Als) Gazyva inhl rituximab-refractory atezolizumab bladder cancer 2L atezolizumab NSCLC 2L+ Alecensa (alectinib) ALK+ NSCLC 2L 1 Global filing 2 CHMP positive opinion Q1 16 3 EU only 4 Approved in the US 5 Phase 3 ongoing 6 Approved in the US and Japan New Molecular Entity (NME) Additional Indication (AI) Oncology Immunology Infectious Diseases CardioMetabolism Neuroscience Ophthalmology Other RG-No Roche/Genentech managed CHU Chugai managed IONIS IONIS Managed PRO Proximagen managed RG105 MabThera is branded as Rituxan in US and Japan RG1569 Actemra is branded as RoActemra in EU RG7159 Gazyva is branded as Gazyvaro in EU 51

NME submissions and their additional indications Projects currently in phase 2 and 3 New Molecular Entity Oncology Immunology Infectious Diseases CardioMetabolism Neuroscience Ophthalmology Other lampalizumab (RG7417) geographic atrophy atezolizumab(rg7446)+chemo +pemetrexed NSCLC non-sq 1L crenezumab (RG7412) Alzheimer s V1 receptor antag (RG7314) autism VEGF/ANG2 bimab (RG7716) wamd taselisib ( RG7604) ER+(HER2-neg) BC neoadj basmisanil (RG1662) Down syndrome gantenerumab (RG1450) Alzheimer s idasanutlin (RG7388) AML atezolizumab(rg7446) NSCLC sq 1L (Dx+) olesoxime (RG6083) SMA lebrikizumab (RG3637) COPD lebrikizumab (RG3637) atopic dermatitis lebrikizumab+/-esbriet (RG3637) IPF atezolizumab(rg7446)+chemo + Avastin NSCLC non-sq 1L taselisib ( RG7604) NSCLC sq 2L atezolizumab(rg7446) NSCLC non-sq 1L (Dx+) etrolizumab (RG7413) Crohn s disease ocrelizumab (RG1594) PPMS atezolizumab(rg7446)+ chemo NSCLC sq 1L SERD (RG6046) ER+(HER2-neg) mbc atezolizumab (RG7446) NSCLC adj (Dx+) etrolizumab (RG7413) ulcerative colitis ocrelizumab (RG1594) RMS atezolizumab(rg7446)+ chemo NSCLC non-sq 1L ipatasertib (RG7440) solid tumors atezolizumab (RG7446) MIBC adj TLR7 ago (RG7795) HBV lebrikizumab (RG3637) severe asthma atezolizumab(rg7446) combo Avastin RCC vanucizumab (RG7221) colorectal cancer Venclexta (venetoclax) + Rituxan FL rel/ref danoprevir (RG7227) HCV atezolizumab (RG7446) US* NSCLC 2L+ Venclexta (venetoclax) + Rituxan CLL rel/refractory atezolizumab (RG7446) + abraxane TNBC polatuzumab vedotin (RG7596) heme tumors Venclexta (venetoclax) + Gazyva CLL 1L Flu A MAb (RG7745) influenza atezolizumab (RG7446) US* bladder cancer 2L emicizumab (RG6013) hemophilia A taselisib (RG7604) HER2 neg ER+ mbc codrituzumab (RG7686) liver cancer Venclexta (venetoclax) DLBCL CAP endonuclease inh (RG6152) influenza 2016 2017 2018 2019 and beyond Unless stated otherwise, submissions are planned to occur in US and EU indicates a submission which has occurred with regulatory action pending Status as of April 19, 2016 * EU submission pending 52

Submissions of additional indications for existing products Projects currently in phase 2 and 3 Avastin (US) GBM *Avastin rel. ovarian ca. Pt-sens. Kadcyla+Perjeta HER2-pos. BC neoadj Gazyva DLBCL 1L Perjeta + Herceptin HER2-pos. mbc 2L Gazyva follicular lymphoma 1L Alecensa (alectinib) Alk+ NSCLC 1L Cotellic+paclitaxel TNBC Kadcyla HER2-pos. NSCLC Kadcyla+Perjeta HER2-pos. BC adj. Kadcyla HER2-pos. BC adj. Perjeta + Heceptin HER2-pos. BC adj. Actemra giant cell arteritis Zelboraf melanoma adj. Perjeta+Herceptin HER2-pos. gastric cancer 1L MabThera pemphigus vulgaris Actemra systemic sclerosis obinutuzumab lupus nephritis ranibizumab PDS (US) wamd 2016 2017 2018 2019 and beyond indicates submission to health authorities has occurred *approved in EU Unless stated otherwise, submissions are planned to occur in US and EU. Status as of April 19, 2016 Oncology Immunology Infectious Diseases CardioMetabolism Neuroscience Ophthalmology Other NME 53

Major granted and pending approvals 2016 Approved Pending approval US EU Japan-Chugai Venclexta (venetoclax) 17pdel CLL rel/ref April 2016 Gazyva inhl rituximab-ref. February 2016 Bonviva osteoporosis (oral) January 2016 atezolizumab NSCLC 2L+ Filed February 2016 atezolizumab bladder cancer 2L Filed January 2016 Alecensa (alectinib) ALK+ NSCLC 2L Filed September 2015 Avastin + Tarceva EGFR mut+ NSCLC Filed July 2015 Gazyva inhl rituximab-ref. Filed September 2015 MabThera SC* CLL Filed November 2014 *CHMP pos. opinion Avastin cervical cancer Filed September 2015 Status as of April 19, 2016 Oncology Immunology Infectious Diseases CardioMetabolism Neuroscience Ophthalmology Other NME 54

Roche Group Development pipeline Combinations Phase I (5 NMEs + 16 AIs) Phase II (3 Als) Registration (1 AI) RG6078 RG7155 RG7159 RG7446 RG7446 RG7446 RG7446 RG7446 RG7446 RG7446 RG7446 RG7601 RG7601 RG7802 RG7813 RG7842 RG7876 RG7876 RG7888 RG3616 RG3616 IDO inh + atezolizumab emactuzumab + atezolizumab atezo+zelboraf+/-cotellic atezo+avastin+chemo atezolizumab +Cotellic atezolizumab +ipi/ifn atezo+tarceva/ Alecensa atezolizumab+gazyva atezo+lenalidomide CEA IL2v FP+atezolizumab s.tumors melanoma solid tumors solid tumors solid tumors NSCLC lymphoma CD40 MAb+atezolizumab solid tumors OX40 MAb + atezolizumab solid tumors Gazyva multiple combos heme indications atezolizumab + K/ H+P multiple myeloma Venclexta+Gazyva CLL Venclexta+Cotellic/idasanutlin AML CLL CEA CD3 TCB+atezolizumab ERK inh + Cotellic HER2+BC s. tumors s. tumors solid tumors CD40 MAb+vanucizumab solid tumors Erivedge+Esbriet Erivedge+ruxolitinib s. tumors IPF myelofibrosis RG7421 RG7601 RG3637 RG1273 RG1273 RG1273 RG3502 RG3502 RG7446 RG7446 Venclexta (venetoclax) +Rituxan FL rel/ref TNBC Phase III (13 AIs) atezo+chemo atezolizumab+avastin NSCLC non-sq. 1L NSC RG7446 atezo+chemo+avastin NSCLC non-sq. 1L RG7446 RG7446 RG7446 RG7601 RG7601 Cotellic+paclitaxel lebrikizumab +/- Esbriet Perjeta+Herceptin Perjeta+Herceptin atezolizumab+chemo atezolizumab+abraxane TNBC IPF HER2+ mbc 2L Perjeta+Herceptin HER2+gastric ca 1L Kadcyla + Perjeta Kadcyla + Perjeta HER2+ BC adj HER2+ BC adj HER2+ BC neoadj atezo+chemo+pemetrexed NSCLC non-sq. 1L NSCLC sq. 1L TNBC RCC Venclexta(venetoclax)+RituxanCLL rel/ref Venclexta (venetoclax)+gazyva CLL 1L RG435 1 Avastin+Tarceva 1 EU only New Molecular Entity (NME) Additional Indication (AI) Oncology Immunology EGFR mut+ NSCLC RG-No Roche Genentech managed Status as of April 19, 2016 55

Cancer immunotherapy pipeline overview Phase I (8 NMEs + 19 AIs) Phase II (2 AIs) Registration (1 NME + 1 AI) RG6078 IDO inh solid tumors IMDZ atezo+ny-eso-1 soft tissue sarcoma RG7446 1 atezolizumab bladder cancer 2L RG6078 RG7155 RG7446 RG7446 RG7446 RG7446 RG7446 RG7446 RG7446 RG7446 RG7446 RG7461 RG7802 RG7813 RG7828 RG7876 RG7876 RG7888 RG7888 *INCY *CLDX *CLVS *CRVS *KITE *AMGN *JNJ IDO inh + atezolizumab emactuzumab + atezolizumab s.tumors atezolizumab atezo+zelboraf+/-cotellic atezo+avastin+chemo atezolizumab +Cotellic atezolizumab +ipi/ifn atezo+tarceva atezolizumab+gazyva atezo+lenalidomide/daratumumab atezolizumab + K/HP FAP IL2v FP OX40 MAb solid tumors solid tumors solid tumors solid tumors NSCLC EGFR+ lymphoma CEA CD3 TCB + atezolizumab s. tumors CD40 MAb+atezolizumab solid tumors atezolizumab + IDO inh atezolizumab+varlilumab solid tumors MM CEA IL2v FP+atezolizumab solid tumors CD20/CD3 bimab m. melanoma HER2+ BC solid tumors hem tumors CD40 MAb+vanucizumab solid tumors solid tumors OX40 MAb + atezolizumab solid tumors atezo+rociletinib atezo+a2ai atezo+cd19 CAR-T atezo+talimogene laherp. atezo+daratumumab solid tumors solid tumors EGFRmut+ NSCLC solid tumors TNBC, CRC solid tumor NHL NSC SNDX atezo+entinostat TNBC RG7446 NSC RG7446 RG7446 RG7446 RG7446 RG7446 RG7446 RG7446 RG7446 RG7446 Phase III (10 AIs) atezo+chemo atezolizumab+avastin NSCLC non-sq. 1L atezo+chemo+avastin NSCLC non-sq. 1L atezo+chemo+pemetrexed NSCLC non-sq. 1L atezolizumab+chemo atezolizumab Dx+ NSCLC sq. 1L NSCLC sq. 1L atezolizumab Dx+ NSCLC non-sq. 1L atezolizumab Dx+ atezolizumab+abraxane NSCLC adj TNBC RCC atezolizumab muscle inv. bladder ca adj RG7446 1 atezolizumab 1 Phase 3 ongoing New Molecular Entity (NME) Additional Indication (AI) Oncology RG-No Roche Genentech managed NSCLC 2L *external collaborations: INCY- Incyte INCB024360, CLDX - Celldex CD27 MAb; CLVS Clovis EGFRi, CRVS Corvus CPI-444, KITE Kite KTE-C19, AMGN Amgen oncolytic virus, JNJ Janssen CD38 MAb., IMDZ Immune Design CMB305, SNDX Syndax HDACi Status as of April 19, 2016 56

Pipeline summary Marketed products additional indications Global Development late-stage trials pred (Roche Pharma Research & Early Development) gred (Genentech Research & Early Development) Roche Group Q1 2016 sales Diagnostics Foreign exchange rate information 57

Alecensa (ALK inhibitor, RG7853, AF802) New CNS-active inhibitor of anaplastic lymphoma kinase Indication Phase/study Treatment-naïve ALK-positive advanced non-small cell lung cancer (NSCLC) Phase III ALEX ALK-positive crizotinib-naïve advanced NSCLC Phase I/II AF-001JP Japanese study # of patients N=286 N=70 Design ARM A: Alecensa 600mg BID ARM A: crizotinib 250mg BID Part 1: Dose escalation monotherapy Part 2: Monotherapy, dose selected based on the results of Part 1 Primary endpoint Progression-free survival Phase I: Determination of recommended dose Phase II: Safety and efficacy Status Recruitment completed Q3 2015 Data expected in 2016 Results published in Lancet Oncology 2013 Jun;14(7):590-8 Approved in Japan July 2014 In collaboration with Chugai 58

Alecensa (ALK inhibitor, RG7853, AF802) New CNS-active inhibitor of anaplastic lymphoma kinase (continued) Indication Phase/study # of patients Design ALK-positive advanced NSCLC after progression on crizotinib treatment Phase I/II AF-002JG/NP28761 US study Phase I: N=36 Phase II: N=85 Part 1: Dose escalation monotherapy Part 2: Monotherapy, dose selected based on the results of Part 1 ALK-positive advanced NSCLC after progression on crizotinib treatment Phase I/II ACCALIA/NP28673 Global study N=130 Part 1: Dose escalation monotherapy Part 2: Monotherapy, dose selected based on the results of Part 1 Primary endpoint Phase I: Determination of recommended dose Phase II: Safety and efficacy Phase I: Determination of recommended dose Phase II: Safety and efficacy Status Phase I data presented at ECC 2013 Phase I full cohort including CNS data published in Lancet Oncology 2014, Sept.15(10):1119-28 Phase II FPI Q3 2013 Primary analysis positive Q1 2015 Data presented at ASCO 2015 Updated data presented at WCLC Phase II FPI Q3 2013 Primary analysis positive Q4 2014 Updated analysis in Q1 2015 Data presented at ASCO 2015 Updated data presented at ECC 2015 Filed Q2 (US) and Q3 (EU) 2015 Priority review granted by FDA Q3 2015 Breakthrough therapy designation granted by the FDA June 2013 Approved in US Q4 2015 In collaboration with Chugai ECC=European Cancer Congress; ASCO=American Society of Clinical Oncology; WCLC=World Conference on Lung Cancer 59

Avastin Ovarian cancer clinical development programme Indication Relapsed platinum-sensitive ovarian cancer Phase/study Phase III OCEANS Phase III GOG-0213 # of patients N=484 N=674 Design ARM A: Carboplatin, gemcitabine, and concurrent placebo for 6-10 cycles, followed by placebo alone until disease progression ARM B: Carboplatin, gemcitabine, and concurrent Avastin for 6-10 cycles, followed by Avastin alone until disease progression. ARM A: carboplatin and paclitaxel ARM B: carboplatin, paclitaxel and Avastin (from cycle 2 onwards until disease progression). Avastin dose 15 mg/kg q3 weeks 15 mg/kg q3 weeks Primary endpoint Progression-free survival Overall survival Status Primary endpoint met Q1 2011 EMA approval received Q4 2012 Final data presented at SGO 2014 FDA submission planned in 2016 Study showed a 4.9 mo overall survival benefit Presented SGO Q1 2015 Filing planned in US and EU in 2016 SGO=Society of Gynecologic Oncology 60

Avastin Brain and breast cancer clinical development programmes Indication Phase/study Newly diagnosed glioblastoma Phase III AVAglio First-line HER2-negative metastatic breast cancer Phase III MERiDiAN # of patients N=920 N=480 Design ARM A: Concurrent radiation and temozolomide plus placebo; followed by maintenance TMZ plus placebo for 6 cycles; then placebo until disease progression ARM B: Concurrent radiation and TMZ plus Avastin; followed by maintenance TMZ plus Avastin for 6 cycles; then Avastin (15mg/kg q3 weeks) monotherapy until disease progression ARM A: Paclitaxel + Avastin ARM B: Paclitaxel + placebo Avastin dose 10 mg/kg q2 weeks or 15 mg/kg q3 weeks 10 mg/kg q2 weeks Primary endpoint Progression-free survival Overall survival PFS in ITT PFS in patients with high plasma VEGF-A Status Co-primary endpoint of PFS met Q3 2012 Overall survival data presented at ASCO 2013 Filed in EU Q1 2013 Negative CHMP opinion Q3 2014 US filing pending Co-primary endpoints met Q1 2015 Data presented at ECC 2015 Data to be submitted to EMEA and Swiss Medic as part of post-marketing commitment TMZ=temozolomide ASCO=American Society of Clinical Oncology; ECC=European Cancer Congress 61

Cotellic (RG7421, GDC-0973) Selective small molecule inhibitor of mitogen-activated protein kinase kinase Indication First-line metastatic triple negative breast cancer Relapsed or Refractory AML not eligible for cytotoxic therapy Phase/study Phase II COLET Phase 1 # of patients N=112 N=140 Design ARM A: Cotellic plus paclitaxel ARM B: placebo plus paclitaxel Phase I (dose escalation) ARM A: Cotellic plus Venclexta ARM B: idasanutlin plus Venclexta Phase II (expansion) ARM A: Cotellic plus Venclexta ARM B: idasanutlin plus Venclexta Primary endpoint Progression-free survival, safety Safety and efficacy Status FPI Q1 2015 FPI Q1 2016 In collaboration with Exelixis 62

Cotellic (RG7421, GDC-0973) Selective small molecule inhibitor of mitogen-activated protein kinase kinase (continued) Indication Locally advanced or metastatic tumours Previously untreated metastatic melanoma BRAF mutation positive Solid tumours Phase/study Phase I Phase I Phase I # of patients N=90 N=44 N=142 Design ARM A: Dose-finding - Cotellic plus atezolizumab (PD-L1 MAb) ARM B: Dose-expansion - Cotellic plus atezolizumab (PD- L1 MAb) Dose-finding study of Cotellic + atezolizumab (PD-L1 MAb) + Zelboraf 1 and atezolizumab (PD- L1 MAb) +Zelboraf 1 combinations Dose-finding study of Cotellic plus RG7842 2 (ERK inhibitor) Primary endpoint Safety Safety/PK Safety and tolerability Status FPI Q4 2013 FPI Q4 2012 FPI Q2 2015 In collaboration with Exelixis 1 Zelboraf In collaboration with Plexxikon, a member of Daiichi Sankyo Group; 2 RG7842 in collaboration with Array BioPharma AML=Acute Myeloid Leukemia 63

Erivedge A novel small molecule inhibitor of the hedgehog signalling pathway Indication Locally advanced or metastatic basal cell carcinoma Idiopathic pulmonary fibrosis Intermediate- or high-risk myelofibrosis (MF) Phase/study Phase II STEVIE Phase Ib ISLAND 2 Phase I MYLIE # of patients N=1,200 N=20 N=94 Design Single ARM: 150 mg Erivedge orally once daily Erivedge plus Esbriet ARM A: Erivedge + ruxolitinib ARM B: placebo + ruxolitinib Primary endpoint Safety: Incidence of adverse events Safety and tolerability Safety and efficacy Status FPI Q2 2011 Recruitment completed Q3 2014 Interim data presented at SMR 2014 FPI Q1 2016 FPI Q1 2016 In collaboration with Curis; SMR=Society for Melanoma Research 64

Gazyva/Gazyvaro Oncology development programme Indication Previously untreated or relapsed/refractory chronic lymphocytic leukemia Diffuse large B-cell lymphoma (DLBCL) Phase/study Phase III GREEN Phase III GOYA # of patients N=800 N=1,418 Design Primary endpoint Single-arm cohort study: Gazyva alone or in combination with different chemotherapy regimens (FC, bendamustine or Clb), investigation of different strategies to reduce IRRs Safety in combination with different chemotherapy regimens ARM A: Gazyva 1000mg IV plus CHOP ARM B: MabThera/Rituxan plus CHOP Progression-free survival Status FPI Q4 2013 Initial safety data presented at ASH 2014 Bendamustine combination cohort efficacy data presented at ASH 2015 Recruitment completed Q2 2014 Trial continues after interim analysis in 2015 Final data expected in 2016 In collaboration with Biogen CHOP=Cyclophosphamide, Doxorubicin, Vincristine and Prednisone; ASH=American Society of Hematology 65

Gazyva/Gazyvaro Oncology development programme (continued) Indication Phase/study Indolent non-hodgkin s lymphoma MabThera/Rituxan refractory Phase III GADOLIN Induction and maintenance study Front-line indolent non-hodgkin s lymphoma Phase III GALLIUM Induction and maintenance study # of patients N=411 N=1,401 Design ARM A: Gazyva 1000mg IV plus bendamustine followed by Gazyva mainteinance ARM B: bendamustine ARM A: Gazyva 1000mg IV plus chemotherapy followed by Gazyva maintenance ARM B: MabThera/Rituxan plus chemotherapy followed by MabThera/Rituxan maintenance Chemotherapy: For follicular lymphoma: CHOP, CVP or bendamustine For non-follicular lymphoma: physician s choice Primary endpoint Progression-free survival Progression-free survival Status Trial stopped at interim for efficacy Q1 2015 Data presented at ASCO 2015 Filed globally Q3 2015 Approved by the FDA Q1 2016 after priority review Recruitment completed Data expected in 2017 In collaboration with Biogen CHOP=Cyclophosphamide, Doxorubicin, Vincristine and Prednisone; CVP=Cyclophosphamide, Vincristine and Prednisolone; ; ASCO= American Society of Clinical Oncology 66

Obinutuzumab (GA101, RG7159) Immunology development programme Indication Lupus nephritis Hypersensitized adult participants with end stage renal disease Phase/study Phase II NOBILITY Phase I # of patients N=120 N=25 Design ARM A: Gazyva 1000mg IV plus mycophenolate mofetil ARM B: placebo IV plus mycophenolate mofetil Cohort 1: single dose of Gazyva Cohort 2: repeated doses of Gazyva Primary endpoint Percentage of participants who achieve Complete Renal Response (CRR) Safety Status FPI Q4 2015 FPI Q4 2015 In collaboration with Biogen 67

Kadcyla Evaluating new treatment options in HER2-positive early breast cancer Indication HER2-positive neoadjuvant breast cancer HER2-positive early breast cancer high-risk patients Operable HER2-positive early breast cancer HER2-positive advanced (2L+) NSCLC Phase/study Phase III KRISTINE Phase III KATHERINE Phase III KAITLIN Phase II # of patients N=444 N=1,484 N=1,850 N=40 Design Before surgery patients will receive 6 cycles of: ARM A: Herceptin plus Perjeta plus docetaxel plus carboplatin ARM B: Kadcyla plus Perjeta After surgery patients will receive: ARM A: Herceptin plus Perjeta ARM B: Kadcyla plus Perjeta ARM A: Kadcyla 3.6mg/kg q3w ARM B: Herceptin Following surgery and antracycline-based therapy: ARM A: Herceptin 6mg/kg q3w plus Perjeta 420 mg/kg q3w plus chemo ARM B: Kadcyla 3.6mg/kg q3w plus Perjeta 420mg/kg q3w plus chemo Single-agent Kadcyla 3.6 mg/kg Primary endpoint Pathologic Complete Response (pcr) Invasive disease-free survival (IDFS) Invasive disease-free survival (IDFS) Overall response rate and safety Status Enrolment completed Q2 2015 Data expected in 2016 Enrolment completed Q4 2015 Data expected in 2018 Enrolment completed Q2 2015 Data expected in 2019 FPI Q4 2014 In collaboration with ImmunoGen, Inc. 68

Lucentis Anti-VEGF antibody fragment for treatment of ocular diseases Indication AMD port delivery device (Ranibizumab Port Delivery System) Phase/study Phase II LADDER # of patients N=220 Design Four arm study: Lucentis monthly intravitreal control vs. 3 ranibizumab formulations delivered via implant Primary endpoint Time to first refill Status FPI Q3 2015 In collaboration with Forsight and Novartis AMD=age-related macular degeneration 69

MabThera/Rituxan Oncology and immunology development programmes Indication Previously untreated chronic lymphocytic leukemia Moderate to severely active pemphigus vulgaris Phase/study Phase Ib SAWYER Subcutaneous study (ex-us) Phase III PEMPHIX # of patients N=225 N=124 Design Two-stage design: - Stage 1 (dose-finding, N=55) - Stage 2 (N=170): CLL dose confirmation: ARM A: MabThera IV plus chemotherapy (fludarabine and cyclophosphamide) ARM B: MabThera 1600mg SC plus chemotherapy (fludarabine and cyclophosphamide) ARM A: Rituxan ARM B: mycophenolate mofetil Primary endpoint Part 1: PK (dose selection) Part 2: PK of MabThera IV versus MabThera SC (arm A vs. arm B) Proportion of patients who achieve a sustained complete remission Status Stage 2 data confirmed non-inferior PK and comparable safety/efficacy of MabThera 1600mg SC vs. MabThera IV Presented at ASH 2014 CHMP positive opinion April 2016 FPI Q2 2015 Subcutaneous MabThera : applies Enhanze technology, partnered with Halozyme ASH=American Society of Hematology 70

Perjeta First in a new class of HER dimerization inhibitors Indication Adjuvant HER2-positive breast cancer Neoadjuvant/adjuvant HER2-positive breast cancer Phase/ study Phase III APHINITY Phase II BERENICE # of patients N=4,803 N=401 Design Primary endpoint ARM A: Perjeta (840mg loading, 420 q3w) plus Herceptin for 52 weeks plus chemotherapy (6-8 cycles) ARM B: placebo plus Herceptin (52 weeks) plus chemotherapy (6-8 cycles) Invasive disease-free survival (IDFS) Neoadjuvant treatment: ARM A: ddac q2w x4 cycles followed by weekly paclitaxel for 12 weeks, with P+H x4 cycles ARM B: FEC+P+H x4 cycles followed by docetaxel+p+h x4 cycles Adjuvant treatment: P+H q3w to complete 1 year of HER2 therapy Hormonal and radiation therapy as indicated Safety Status Recruitment completed Q3 2013 Data expected in 2016 Enrollment completed Q3 2015 Data expected in 2016 ddac=dose-dense doxorubicin plus cyclophosphamide; FEC = fluorouracil, epirubicin, and cyclophosphamide 71

Perjeta First in a new class of HER dimerization inhibitors (continued) Indication Second-line HER2-positive metastatic breast cancer Advanced HER2-positive gastric cancer Phase/ study Phase III PHEREXA Phase III JACOB # of patients N=450 N=780 Design ARM A: Herceptin plus Xeloda ARM B: Perjeta plus Herceptin and Xeloda ARM A: Perjeta (840mg loading, 420mg q3w) plus Herceptin and chemotherapy ARM B: placebo plus Herceptin and chemotherapy Primary endpoint Progression-free survival Overall survival Status Recruitment completed Q3 2013 Data in-house Data to be presented at ASCO 2016 Recruitment completed Q1 2016 Data expected in 2017 ASCO=American Society of Clinical Oncology 72

Zelboraf A selective novel small molecule that inhibits mutant BRAF Indication Adjuvant therapy in patients with resected cutaneous BRAF mutation positive melanoma Phase/study Phase III BRIM8 # of patients N=475 Design 52-week treatment ARM A: Zelboraf 960mg bid ARM B: Placebo Primary endpoint Disease-free survival Status Enrolment completed Q2 2015 Data expected in 2017 In collaboration with Plexxikon, a member of Daiichi Sankyo Group See also combinations with: Cotellic (MEK inhibitor) and atezolizumab (PD-L1 MAb) 73

Actemra/RoActemra Interleukin 6 receptor inhibitor Indication Systemic sclerosis Giant cell arteritis Phase/study Phase II fasscinate Proof-of-concept study Phase III focussced Phase III GiACTA # of patients N=86 N=210 N=250 Design Primary endpoint Blinded 48-week treatment with weekly dosing: ARM A: Actemra SC 162mg ARM B: Placebo SC Open-label weekly dosing at weeks 49 to 96: Actemra SC 162mg Change in modified Rodnan skin score (mrss) at week 24 Safety Blinded 48-week treatment with weekly dosing: ARM A: Actemra SC 162mg ARM B: Placebo SC Open-label weekly dosing at weeks 49 to 96: Actemra SC 162mg Change in modified Rodnan skin score (mrss) at week 48 Part 1: 52-week blinded period ARM A: Actemra SC 162mg qw + 26 weeks prednisone taper ARM B: Actemra SC 162mg q2w + 26 weeks prednisone taper ARM C: Placebo+ 26 weeks prednisone taper ARM D: Placebo+ 52 weeks prednisone taper Part II: 104-week open label extension patients in remission followed off of the study drug; Patients with active disease receive open label Actemra SC 162mg qw Proportion of patients in sustained remission at week 52 Status 48 week data presented at EULAR 2015 Primary and all key secondary endpoints showed trend for improved efficacy Breakthrough designation granted Q1 2015 FPI Q4 2015 Recruitment completed Q2 2015 Data expected in 2016 In collaboration with Chugai; ACR=American College of Rheumatology 74

Pipeline summary Marketed products additional indications Global Development late-stage trials pred (Roche Pharma Research & Early Development) gred (Genentech Research & Early Development) Roche Group Q1 2016 sales Diagnostics Foreign exchange rate information 75

Tecentriq (atezolizumab, PD-L1 MAb, RG7446) Novel approach in cancer immunotherapy Indication 1L non-squamous NSCLC PD-L1-selected patients 1L non-squamous NSCLC 1L non-squamous NSCLC 1L non-squamous NSCLC Phase/study Phase III IMpower 110 Phase III IMpower 150 Phase III IMpower 130 Phase III IMpower 132 # of patients N=400 N=1,200 N=550 N=680 Design ARM A: atezolizumab monotherapy ARM B: carboplatin or cisplatin + pemetrexed ARM A: atezolizumab + Avastin + paclitaxel + carboplatin ARM B: atezolizumab + paclitaxel + carboplatin ARM C: Avastin + paclitaxel + carboplatin ARM A: atezolizumab + nab-paclitaxel + carboplatin ARM B: nab-paclitaxel + carboplatin ARM A: atezolizumab + carboplatin or cisplatin + pemetrexed ARM B: carboplatin or cisplatin + pemetrexed Primary endpoint Progression-free survival Progression-free survival Progression-free survival Progression-free survival Status FPI Q3 2015 FPI Q2 2015 FPI Q1 2015 FPI April 2016 76

Tecentriq (atezolizumab, PD-L1 MAb, RG7446) Novel approach in cancer immunotherapy Indication Adjuvant NSCLC PD-L1-selected patients 1L squamous NSCLC PD-L1-selected patients 1L squamous NSCLC Phase/study Phase III IMpower 010 Phase III IMpower 111 Phase III IMpower 131 # of patients 845 N=400 N=1200 Design Following adjuvant cisplatinbased chemotherapy ARM A: atezolizumab ARM B: best supportive care ARM A: atezolizumab monotherapy ARM B: gemcitabine + cisplatin or carboplatin ARM A: atezolizumab + nabpaclitaxel + carboplatin ARM B: atezolizumab + paclitaxel + carboplatin ARM C: nab-paclitaxel + carboplatin Primary endpoint Disease-free survival Progression-free survival Progression-free survival Status FPI Q3 2015 FPI Q2 2015 FPI Q2 2015 77

Tecentriq (atezolizumab, PD-L1 MAb, RG7446) Novel approach in cancer immunotherapy Indication Metastatic NSCLC 2L metastatic NSCLC Locally advanced or PD-L1 positive Phase/study Phase III OAK Phase II FIR Locally advanced or metastatic NSCLC PD-L1 positive Phase II BIRCH Locally advanced or metastatic NSCLC (2L/3L) Phase II POPLAR Non-small cell lung cancer # of patients N=1,225 N=130 N=635 N=287 N=32 Design Primary endpoint Status ARM A: atezolizumab 1200mg q3w ARM B: docetaxel Single arm study: atezolizumab 1200mg q3w Single arm study: atezolizumab 1200mg q3w ARM A: atezolizumab 1200mg q3w ARM B: docetaxel Overall survival Overall response rate Objective response rate Overall survival Safety Recruitment completed Q2 2015 Readout in 2016 Recruitment completed Q2 2014 Data presented at ASCO 2015 Recruitment completed Q4 2014 Primary analysis presented at ECC 2015 Filed with the FDA Q1 2016 Priority review granted Q1 2016 Recruitment completed Q2 2014 Interim data presented at ASCO 2015 Primary analysis presented at ECC 2015 Results published in Lancet, March 9 2016 Updated data to be presented at ASCO 2016 Phase I atezolizumab plus Tarceva 1 or Alecensa FPI Q1 2014 FPI in Alecensa arm Q3 2015 1 Tarceva is a registered trademark of OSI Pharmaceuticals, LLC, a subsidiary of Astellas US, LLC ASCO=American Society of Clinical Oncology; ECC=European Cancer Congress 78

Tecentriq (atezolizumab, PD-L1 MAb, RG7446) Novel approach in cancer immunotherapy Indication Adjuvant high risk muscle invasive bladder cancer PD-L1-positive patients Locally advanced or metastatic urothelial bladder cancer Phase/study Phase III IMvigor 010 Phase III IMvigor 211 Phase II IMvigor 210 # of patients N=440 N=930 N=439 Design After cystectomy: ARM A: atezolizumab monotherapy ARM B: observation Patients who progressed on at least one platinum-containing regimen will receive: ARM A: atezolizumab 1200mg q3w ARM B: chemotherapy (vinflunine, paclitaxel or docetaxel) Cohort 1: Treatment-naive and cisplatin-ineligible patients Cohort 2: Patients with disease progression following or during platinum-containing treatment Primary endpoint Progression-free survival Overall survival Objective response rate Status FPI October 2015 Enrollment completed Q1 2016 Recruitment completed Q1 2015 Primary analysis presented at ECC 2015 Filed in US Q1 2016 Priority review granted Q1 2016 Results published in Lancet, Mar 4 2016 Cohort 1 and updated cohort 2 data to be presented at ASCO 2016 ECC=European Cancer Congress; ASCO=American Society of Clinical Oncology 79

Tecentriq (atezolizumab, PD-L1 MAb, RG7446) Novel approach in cancer immunotherapy Indication Untreated advanced renal cell carcinoma Phase/study Phase III IMmotion 151 Phase II IMmotion 150 # of patients N=830 N=305 Design ARM A: atezolizumab plus Avastin ARM B: sunitinib ARM A: atezolizumab plus Avastin ARM B: atezolizumab; following PD: atezolizumab plus Avastin ARM C: sunitinib; following PD: atezolizumab plus Avastin Primary endpoint Progression-free survival and overall survival co-primary Progression-free survival Status FPI Q2 2015 Recruitment completed Q1 2015 Data expected in 2016 80

Tecentriq (atezolizumab, PD-L1 MAb, RG7446) Novel approach in cancer immunotherapy Indication Phase/study Previously untreated metastatic triple negative breast cancer Phase III IMpassion 130 Metastatic breast cancer and locally advanced early breast cancer HER2- positive Phase I # of patients N=900 N=59 Design Primary endpoint ARM A: atezolizumab plus nab-paclitaxel ARM B: placebo plus nab-paclitaxel Progression-free survival and overall survival co-primary Cohort 1A (metastatic): atezolizumab + Perjeta +Herceptin Cohort 1B (metastatic): atezolizumab + Kadcyla Cohort 2A (neoadjuvant): atezolizumab + Perjeta +Herceptin followed by docetaxel + carboplatin + Perjeta +Herceptin Cohort 2B (neoadjuvant): atezolizumab + Kadcyla followed by docetaxel + carboplatin + Perjeta +Herceptin Cohort 2C (expansion on cohort 1B): atezolizumab + Kadcyla Safety Status FPI Q3 2015 FPI Q4 2015 81

Tecentriq (atezolizumab, PD-L1 MAb, RG7446) Novel approach in cancer immunotherapy Indication Relapsed/refractory follicular lymphoma and DLBCL Multiple myeloma Myelodysplastic syndrome (MDS) 1L FL and 1L DLBCL Relapsed or refractory FL Phase/study Phase I Phase I Phase I Phase I Phase I # of patients N=46 N=46 N=46 N=92 N=46 Design Stage 1: Safety evaluation atezolizumab plus Gazyva Stage 2: expansion atezolizumab plus Gazyva atezolizumab monotherapy atezolizumab +lenalidomide atezolizumab + daratumumab atezolizumab + lenalidomide + daratumumab atezolizumab monotherapy and azacitidine combination cohorts atezolizumab + Gazyva + bendamustine atezolizumab + Gazyva + CHOP atezolizumab + Gazyva + lenalidomide Primary endpoint Safety Safety Safety Safety and efficacy Safety and efficacy Status FPI Q4 2014 FPI Q3 2015 FPI Q3 2015 FPI Q4 2015 FPI Q4 2015 FL=follicular lymphoma; DLBCL=diffuse large B cell lymphoma 82

Tecentriq (atezolizumab, PD-L1 MAb, RG7446) Novel approach in cancer immunotherapy Indication Solid tumours Solid tumours Solid tumours Solid tumours Phase/study Phase I Phase I Phase I Phase I # of patients N=60 N=225 N=160 N=110 Design ARM A: hepatocellular carcinoma -atezolizumab + Avastin ARM B: gastric cancer -atezolizumab + Avastin + oxaliplatin+leucovorin+5-fu ARM C: HER2-negative panreatic cancer -atezolizumab + nabpaclitaxel+gemcitabine ARM A: atezolizumab + Avastin ARM B: atezolizumab + Avastin + FOLFOX ARM C: atezolizumab + carboplatin + paclitaxel ARM D: atezolizumab + carboplatin+ pemetrexed ARM E: atezolizumab + carboplatin+ nab-paclitaxel ARM F: atezolizumab + nab-paclitaxel Part 1: sequential administration of atezolizumab and RG7876 (CD40 MAb) Part 2: concomitant administration of atezolizumab and RG7876 (CD40 MAb) Part 3: study drugs schedule in specific indication per Part 2 atezolizumab in combination with emactuzumab (CSF-1R MAb) Part 1: dose escalation Part 2: expansion Primary endpoint Safety Safety/PK Safety Safety Status FPI April 2016 FPI Q2 2012 Chemo combination data in NSCLC presented at ASCO, WCLC and ECC 2015 Updated CRC data presented at AACR 2016 Updated TNBC data to be presented at ASCO 2016 FPI Q4 2014 FPI Q1 2015 ASCO=American Society of Clinical Oncology; ECC=European Cancer Congress SABCS=San Antonio Breast Cancer Symposium; WCLC=World Conference on Lung Cancer 83

Tecentriq (atezolizumab, PD-L1 MAb, RG7446) Novel approach in cancer immunotherapy Indication Solid tumours Solid tumours Locally advanced or metastatic solid tumours CEA-positive solid tumours Phase/study Phase I Phase I Phase I Phase I # of patients N=224 N=360 N=200 N=90 Design atezolizumab in combination with RG6078 (IDO inhibitor), dose escalation and expansion cohorts Stage 1: Dose escalation of atezolizumab plus RG7888 (OX40 MAb) Stage 2: Expansion atezolizumab plus RG7888 (OX40 MAb) ARM A: atezolizumab plus ipilimumab ARM B: atezolizumab plus interferon alpha-2b atezolizumab plus RG7802 (CEA CD3 TCB) Primary endpoint Safety Safety Safety Safety, PK/PD, imaging, biomarkers Status FPI Q3 2015 FPI Q2 2015 Dose escalation data to be presented at ASCO 2016 FPI Q3 2014 FPI Q1 2016 ASCO=American Society of Clinical Oncology 84

Tecentriq (atezolizumab, PD-L1 MAb, RG7446) Novel approach in cancer immunotherapy Indication Previously untreated metastatic melanoma BRAF mutation positive Solid tumours Locally advanced or metastatic solid tumours Phase/study Phase I Phase I Phase I # of patients N=44 N=90 N=689 Design Dose-finding study of atezolizumab + Zelboraf 1 and atezolizumab + Zelboraf 1 + Cotellic (MEK inhibitor) 2 combinations ARM A: Dose-finding atezolizumab plus Cotellic ARM B: Dose-exspansion atezolizumab plus Cotellic Dose escalation study Primary endpoint Safety/PK Safety Safety/PK Status FPI Q4 2012 Zelboraf combination data presented at SMR 2015 FPI Q4 2013 CRC cohort data to be presented at ASCO 2016 FPI Q2 2011 Initial efficacy data presented at ASCO 2013 Updated data presented at ECC 2013 Data from bladder cohort presented at ASCO and ESMO 2014 Data from TNBC cohort presented at AACR 2015 Updated lung and bladder data presented at ASCO 2015 GBM data presented at SNO 2015 1 Zelboraf in collaboration with Plexxikon, a member of Daiichi Sankyo Group; 2 Cotellic in collaboration with Exelixis SMR=Society for Melanoma Research; ASCO=American Society of Clinical Oncology; ECC=European Cancer Congress; SNO=Society for Neuro-Oncology; AACR=American Association for Cancer Research 85

Polatuzumab vedotin (RG7596) Antibody drug conjugate targeting CD79b for the treatment of B-cell malignancies Indication Non-Hodgkin's lymphoma Non-Hodgkin s lymphoma Relapsed or refractory follicular lymphoma and DLBCL Phase Phase II ROMULUS Phase Ib/II Phase Ib/II # of patients N=228 N=104 N=224 Design ARM A: pinatuzumab vedotin plus Rituxan ARM B: polatuzumab vedotin plus Rituxan ARM C: polatuzumab vedotin plus Gazyva PhIb: dose escalation PhII: polatuzumab vedotin in combination with Rituxan or Gazyva and CHP non-randomized PIb: dose escalation PhII: polatuzumab vedotin + BR vs. BR PhII expansion: polatuzumab vedotin +Gazyva non-randomized Primary endpoint Safety and anti-tumour activity Safety and response by PET/CT Safety and response by PET/CT Status Recruitment in arms A&B completed Q1 2014 FPI in Gazyva arm C Q1 2015 Updated data presented at ASCO, ICML and EHA 2015 Updated data to be presented at ASCO 2016 FPI Q4 2013 Initial data presented at ASH 2015 Updated data to be presented at ASCO 2016 FPI Q4 2014 In collaboration with Seattle Genetics ASCO=American Society of Clinical Oncology; ICML=international conference on malignant lymphoma; EHA=European Hematology Association; ASH=American Society of Hematology; BR=bendamustine and Rituxan; CHP=Cyclophosphamide, Hydroxydoxorubicin, Prednisone; DLBCL=diffuse large B cell lymphoma 86

Polatuzumab vedotin (RG7596) Antibody drug conjugate targeting CD79b for the treatment of B-cell malignancies Indication Relapsed or refractory FL or DLBCL Relapsed or refractory FL and DLBCL Phase Phase I/II Phase I/II # of patients N=116 N=116 Design Dose escalation cohort: polatuzumab vedotin + Gazyva + venetoclax Expansion cohort: DLBCL polatuzumab vedotin + Gazyva + venetoclax Expansion cohort: FL polatuzumab vedotin + Gazyva + venetoclax Dose escalation cohort: polatuzumab vedotin + Gazyva + lenalidomide Expansion cohort: DLBCL polatuzumab vedotin + Gazyva + lenalidomide Expansion cohort: FL polatuzumab vedotin + Gazyva + lenalidomide Primary endpoint Percentage of participants with CR Percentage of participants with CR Status FP Q1 2016 FPI Q1 2016 In collaboration with Seattle Genetics; FL=follicular lymphoma; DLBCL=diffuse large B cell lymphoma 87

Taselisib (RG7604, GDC-0032) Mutant-selective PI3 kinase inhibitor Indication Phase HER2-negative ER-positive metastatic breast caner patients who progressed after aromatase inhibitor therapy Phase III SANDPIPER Neoadjuvant HER2-negative ERpositive breast cancer Phase II LORELEI # of patients N=600 N=330 Design ARM A: taselisib plus fulvestrant ARM B: placebo plus fulvestrant ARM A: taselisib plus letrozole ARM B: placebo plus letozole Primary endpoint Progression-free survival Response rate and pcr Status FPI Q2 2015 FPI Q4 2014 ER=estrogen receptor 88

Taselisib (RG7604, GDC-0032) Mutant-selective PI3 kinase inhibitor Indication Solid tumours and HER2- negative HR-positive breast cancer HER2-negative HR-positive locally recurrent or metastatic breast cancer PI3KCAmut-pos. 2L squamous NSCLC Lung Master Protocol Phase Phase I/II Phase I Phase II Lung-MAP # of patients N=320 N=65 N=120 Design Phase I taselisib taselisib plus letrozole or fulvestrant taselisib plus docetaxel taselisib plus paclitaxel taselisib vs. chemo Phase II taselisib (multiple doses) plus letrozole or fulvestrant Primary endpoint Safety/PK/efficacy Safety Progression-free survival Status Recruitment completed Q2 2014 Updated data presented at SABCS 2014 FPI Q2 2013 FPI Q2 2014 SABCS=San Antonio Breast Cancer Symposium; HR=hormone receptor 89

Venclexta (venetoclax, RG7601, ABT-199/GDC- 0199) Novel small molecule Bcl-2 selective inhibitor Indication Untreated CLL patients with coexisting medical conditions Relapsed or refractory CLL Relapsed or refractory CLL with 17p deletion Phase/study Phase III CLL14 Phase III MURANO Phase II # of patients N=432 N=370 N=100 Design ARM A: Venclexta plus Gazyva ARM B: chlorambucil plus Gazyva ARM A: Venclexta plus Rituxan ARM B: Rituxan plus bendamustine Single-agent Venclexta Primary endpoint Progression-free survival Progression-free survival Safety/MTD Status FPI Q4 2014 Recruitment completed Q3 2015 Data expected in 2017 Recruitment completed Q2 2014 Breakthrough designation granted in Q2 2015 Efficacy endpoint met Filed globally Q4 2015 Priority review granted Q1 2016 Approved by the FDA April 2016 Joint project with AbbVie, in collaboration with WEHI (The Walter and Eliza Hall Institute) CLL=Chronic Lymphocytic Leukemia 90

Venclexta (venetoclax, RG7601, ABT-199/GDC- 0199) Novel small molecule Bcl-2 selective inhibitor Indication Relapsed or refractory CLL Relapsed CLL and SLL Relapsed or refractory or previously untreated CLL Relapsed or refractory or previously untreated CLL Phase/stud y # of patients Phase II Phase Ib Phase Ib Phase Ib N=40 N=50 N=70 N=74 Design Venclexta after ibrutinib therapy Venclexta after idelalisib therapy Dose-escalation study in combination with MabThera/Rituxan Venclexta in combination with MabThera/Rituxan and bendamustine Venclexta in combination with Gazyva Primary endpoint Overall response rate Safety/MTD Safety/MTD Safety/MTD Status FPI Q3 2014 Data presented at ASH 2015 Recruitment completed Q1 2015 Data presented at ASCO 2014 and EHA 2015 Updated data presented at ASH 2015 FPI Q2 2013 Data presented at ASH 2015 FPI Q1 2014 Data presented at ASH 2015 Joint project with AbbVie, in collaboration with WEHI (The Walter and Eliza Hall Institute) CLL=Chronic Lymphocytic Leukemia; SLL=Small Lymphocytic Lymphoma ASH=American Society of Hematology; ASCO=American Society of Clinical Oncology; EHA=European hematology association 91

Venclexta (venetoclax, RG7601, ABT-199/GDC- 0199) Novel small molecule Bcl-2 selective inhibitor Indication Relapsed or refractory follicular NHL Front-line (FL) DLBCL Relapsed or refractory FL or DLBCL Phase/study Phase II CONTRALTO Phase I/II CAVALLI Phase I/II # of patients N=156 N=230 N=116 Design ARM A: Venclexta plus Rituxan ARM B: Venclexta plus Rituxan plus bendamustine ARM C: Rituxan plus bendamustine Dose finding: ARM A: Venclexta+R-CHOP ARM B: Venclexta+G-CHOP Expansion: Venclexta+R/G-CHOP Dose escalation cohort: Venclexta+Gazyva+polatuzumab vedotin Expansion cohort: DLBCL Venclexta+Gazyva+polatuzumab vedotin Expansion cohort: FL Venclexta+Gazyva+polatuzumab vedotin Primary endpoint Overall response rate Safety and efficacy Percentage of participants with CR Status FPI Q4 2014 Data expected in 2016 FPI Q2 2014 Data to be presented at ASCO 2016 FP Q1 2016 Joint project with AbbVie, in collaboration with WEHI (The Walter and Eliza Hall Institute) NHL=non-Hodgkin s lymphoma; DLBCL=diffuse large B cell lymphoma ASCO=American Society of Clinical Oncology 92

Venclexta (venetoclax, RG7601, ABT-199/GDC- 0199) Novel small molecule Bcl-2 selective inhibitor Indication Relapsed or refractory FL or DLBCL Relapsed or Refractory NHL Relapsed or Refractory CLL and NHL Phase/study Phase I/II Phase I Phase I # of patients N=116 N=40 N=211 Design Primary endpoint Dose escalation cohort: polatuzumab vedotin + Gazyva + venetoclax Expansion cohort: DLBCL polatuzumab vedotin + Gazyva + venetoclax Expansion cohort: FL polatuzumab vedotin + Gazyva + venetoclax Percentage of participants with CR Dose escalation of Venclexta in combination with Rituxan and bendamustine Overall response rate Status FPI Q1 2016 FPI Q2 2012 Study resumed Q3 2013 Data presented at ASCO 2015 Updated data presented at ASH 2015 Dose-escalation study ARM A: CLL and SLL patients ARM B: NHL and SLL Safety/PK/Response rate FPI Q2 2011 Updated CLL, SLL and NHL (DLBCL and FL) data presented at ASCO 2014 Updated data presented at ASH 2015 Arm A filed for r/r CLL indications Q4 2015 Joint project with AbbVie, in collaboration with WEHI (The Walter and Eliza Hall Institute) NHL=non-Hodgkin s lymphoma; DLBCL=diffuse large B cell lymphoma; CLL=chronic lymphocytic leukemia; SLL=small lymphocytic lymphoma; ASCO=American Society of Clinical Oncology; ASH=American Society of Hematology 93

Venclexta (venetoclax, RG7601, ABT-199/GDC- 0199) Novel small molecule Bcl-2 selective inhibitor Indication Relapsed or refractory multiple myeloma Phase/study Phase I Phase I # of patients N=30 N=30 Design Patients receiving bortezomib and dexamethasone as standard therapy: Dose escalation cohort: Venclexta+bortezomib+dexa methasone Safety expansion cohort: Venclexta+bortezomib+dexa methasone Dose escalation cohort Safety expansion cohort Primary endpoint Safety/MTD Safety/MTD Status FPI Q4 2012 Data presented at ASCO 2015 FPI Q4 2012 Data presented at ASCO 2015 Joint project with AbbVie, in collaboration with WEHI (The Walter and Eliza Hall Institute) ASCO=American Society of Clinical Oncology; ASH=American Society of Hematology 94

Venclexta (venetoclax, RG7601, ABT-199/GDC- 0199) Novel small molecule Bcl-2 selective inhibitor Indication Acute myelogenous leukemia (AML) Relapsed or refractory AML not eligible for cytotoxic therapy Phase/study Phase II Phase Ib Phase I # of patients N=54 N=89 N=140 Design Dose escalation of Venclexta Venclexta (dose escalation) +decitabine Venclexta (dose escalation) +azacitidine Phase I (dose escalation) ARM A: Cotellic+ Venclexta ARM B: idasanutlin+ Venclexta Phase II (expansion) ARM A: Cotellic + Venclexta ARM B: idasanutlin+ Venclexta Primary endpoint Overall response rate Safety Safety and efficacy Status FPI Q4 2013 Data presented at ASH 2014 FPI Q4 2014 Data to be presented at ASH 2015 FPI Q1 2016 Joint project with AbbVie, in collaboration with WEHI (The Walter and Eliza Hall Institute) ASCO=American Society of Clinical Oncology; ASH=American Society of Hematology 95

Emicizumab (RG6013, ACE910) Factor VIII mimetic for treatment of hemophilia A Indication Hemophilia A Phase/study Phase I Study in Japan Phase I/II Study in Japan # of patients N=82 N=18 Design Enrolled 64 HVs and 18 patients Extension study in patients from phase 1 Primary endpoint Exploratory efficacy and safety Exploratory efficacy and safety Status Recruitment completed Q2 2014 Data presented at ASH 2014 Recruitment completed Q4 2014 Data presented at ISTH 2015 In collaboration with Chugai ASH=American Society of Hematology, ISTH=International Society on Thrombosis and Haemostasis 96

Emicizumab (RG6013, ACE910) Factor VIII mimetic for treatment of hemophilia A Indication Hemophilia A patients with inhibitors to factor VIII Hemophilia A Phase/study Phase III Non-Interventional study # of patients N=70 N>90 Design Primary endpoint Patients on episodic treatment prior to study entry: ARM A: episodic treatment + emicizumab prohylaxis ARM B: episodic treatment (no prohylaxis) Patients on prophylactic treatment with bypassing agents prior to study entry: ARM C: emicizumab prohylaxis + episodic treatment Number of bleeds over 24 week period A single arm, multicenter, noninterventional study evaluating bleeding incidence, health-related quality of life and safety in patients with Hemophilia A and inhibitors against Factor VIII under standard-of-care treatment Number of bleeds over time, sites of bleed, type of bleed Status FPI Q4 2015 Inhibitor cohort closed Q4 2015 except China FPI in non-inhibitor and pediatric subjects in Q1 2016 In collaboration with Chugai 97

Crenezumab (RG7412) A humanized monoclonal antibody designed to target all forms of amyloid-beta Indication Prodromal to mild Alzheimer s disease Alzheimer s disease Phase/study Phase III CREAD Phase II ABBY Cognition study Phase II BLAZE Biomarker study # of patients N=750 N=446 N=91 Design ARM A: crenezumab IV q4w ARM B: placebo IV q4w ARM A: crenezumab SC ARM B: crenezumab IV ARM C: placebo ARM A: crenezumab SC ARM B: crenezumab IV ARM C: placebo Primary endpoint CDR-SB at 105 weeks Change in cognition (ADAS-cog) and Clinical Dementia Rating, Sum of Boxes (CDR-SOB) score from baseline to week 73 Status FPI Q1 2016 Enrolment completed Q3 2012 Positive trend in cognition was observed in higher dose for people with milder disease consistently across both studies (ABBY/BLAZE) and across endpoint Data presented at AAIC 2014 Change in brain amyloid load from baseline to week 69 Enrolment completed Q3 2012 Cognition data presented at AAIC 2014 Exploratory amyloid PET analysis suggests reduced amyloid accumulation in ARM B Biomarker data presented at CTAD 2014 In collaboration with AC Immune AAIC=Alzheimer s Association International Conference; CTAD=Clinical Trials on Alzheimer s Disease 98

Crenezumab (RG7412) A humanized monoclonal antibody designed to target all forms of amyloid-beta Indication Phase/study Mild to moderate Alzheimer s disease Phase I Alzheimer s Prevention Initiative (API) Colombia Phase II Cognition study # of patients N=72 N=300 Design ARM A/B: crenezumab dose level I & placebo ARM C/D: crenezumab dose leveli & placebo ARM E/F: crenezumab dose levelii & placebo ARM A: 100 carriers receive crenezumab SC ARM B: 100 carriers receive placebo ARM C: 100 non-carriers receive placebo Primary endpoint Safety (incidence and nature of MRI safety findings) and PK Change on Alzheimer's Prevention Initiative (API) Composite Cognitive Test total score Status FPI Q1 2015 FPI Q4 2013 In collaboration with AC Immune 99

Gantenerumab (RG1450) Fully human monoclonal antibody designed to bind to aggregated forms of amyloid-beta Indication Prodromal Alzheimer s disease Mild Alzheimer s disease Phase/study Phase II/III SCarlet RoAD Phase III Marguerite RoAD # of patients N=799 N=1,000 Design Primary endpoint Status 104-week subcutaneous treatment period ARM A: gantenerumab (225 mg) ARM B: gantenerumab (105 mg) ARM C: placebo Change in CDR-SOB at 2 years Sub-study: change in brain amyloid by PET at 2 years Phase I PET data: Archives of Neurology 2012 Feb;69(2):198-207 Enrolment completed Q4 2013 Dosing stopped due to futility Q4 2014 Data presented at AAIC 2015 FPI in open label extension study Q4 2015 104-week subcutaneous treatment period ARM A: gantenerumab ARM B: placebo Change in ADAS-Cog and CDR-SB at 2 years (co-primary) FPI Q1 2014 FPI Q1 2016 for open label extension In collaboration with Morphosys CDR-SOB=Clinical Dementia Rating scale Sum of Boxes 100

Etrolizumab (RG7413) Humanized monoclonal antibody against beta 7 integrin Indication Ulcerative colitis patients who are TNF naïve Phase/study Phase III HIBISCUS I Induction study Phase III HIBISCUS II Induction study Phase III GARDENIA Sustained remission study # of patients N=350 N=350 N=720 Design ARM A: etrolizumab 105mg SC q4w + adalimumab placebo SC ARM B: etrolizumab placebo SC + adalimumab SC ARM C: etrolizumab placebo SC + adalimumab placebo SC ARM A: etrolizumab 105mg SC q4w + adalimumab placebo SC ARM B: etrolizumab placebo SC + adalimumab SC ARM C: etrolizumab placebo SC + adalimumab placebo SC Time on treatment 54 weeks ARM A: etrolizumab 105mg SC q4w + placebo IV ARM B: placebo SC q4w + inflixumab IV Primary endpoint Induction of remission compared with placebo as determined by the Mayo Clinic Score (MCS) at week 10 Induction of remission compared with placebo as determined by the Mayo Clinic Score (MCS) at week 10 Proportion of patients in sustained clinical remission as determined by Mayo Clinic Score (MCS) at weeks 10, 30 and 54 Status FPI Q4 2014 FPI Q4 2014 FPI Q4 2014 101

Etrolizumab (RG7413) Humanized monoclonal antibody against beta 7 integrin (continued) Indication Phase/study UC patients who are TNF naïve and refractory or intolerant to immunosuppressant and/or corticosteroid treatment Phase III LAUREL Maintenance study UC patients who are refractory or intolerant of TNF inhibitors Phase III HICKORY Induction and maintenance study # of patients N=350 N=800 Design Primary endpoint Induction phase: ARM A: open label etrolizumab 105mg SC q4w Maintenance study: ARM B: etrolizumab 105mg SC q4w ARM C: placebo Maintenance of remission (at week 62) among randomized patients in remission at Week 10 as determined by the Mayo Clinic Score (MCS) Cohort 1 (open-label): ARM A: etrolizumab induction + placebo maintenance ARM B: etrolizumab induction + maintenance Cohort 2 (blinded): ARM A: etrolizumab induction + maintenance ARM B: placebo induction + maintenance Clinical Remission (Mayo Clinic Score, MCS) at Week 14 Remission maintenance (by MCS, at Week 66) among patients with remission at Week 14 Status FPI Q3 2014 FPI Q2 2014 UC=ulcerative colitis 102

Etrolizumab (RG7413) Humanized monoclonal antibody against beta 7 integrin (continued) Indication Moderate to severe ulcerative colitis Moderate to severe ulcerative colitis Phase/study Phase II SPRUCE Open label extension study Phase III COTTONWOOD Open label extension study # of patients N=116 N=2,600 Design Patients who were enrolled in EUCALYPTUS study and meet enrolment criteria will receive etrolizumab 105 SC q4w Patients who were previously enrolled in etrolizumab phase III studies and meet enrolment criteria will receive etrolizumab 105 SC q4w Primary endpoint Safety Long-term efficacy as determined by partial Mayo Clinic Score (pmcs) Incidence of adverse events Status Recruitment completed FPI Q3 2014 103

Etrolizumab (RG7413) Humanized monoclonal antibody against beta 7 integrin (continued) Indication Moderately to severely active Crohn s disease Moderately to severely active Crohn s disease Phase/study Phase III BERGAMOT Phase III JUNIPER # of patients N=1,250 N=1,250 Design ARM A: etrolizumab SC 210 mg (induction only) ARM B: etrolizumab SC 105 mg and maintainance ARM C: placebo Etrolizumab SC 105mg q4w Primary endpoint Induction and maintenance of clinical remission Safety Status FPI Q1 2015 FPI Q2 2015 104

Lampalizumab (RG7417) Antibody fragment to selectively block activation of alternative complement pathway Indication Geographic atrophy (GA) secondary to age-related macular degeneration Phase/study Phase III CHROMA Phase III SPECTRI Phase II # of patients N=936 N=936 N=84 Design ARM A: lampalizumab 10mg q4w ARM B: lampalizumab 10mg q6w ARM C: placebo ARM A: lampalizumab 10mg q4w ARM B: lampalizumab 10mg q6w ARM C: placebo ARM A: lampalizumab 10mg q2w ARM B: lampalizumab 10mg q4w ARM C: placebo Primary endpoint Primary: change in GA area Secondary: change in BCVA and in additional measures of visual function Primary: change in GA area Secondary: change in BCVA and in additional measures of visual function Change in GA area Status FPI Q3 2014 Design presented at EURETINA 2014 Fast track designation received Q4 2014 FPI Q3 2014 Design presented at EURETINA 2014 Fast track designation received Q4 2014 FPI Q4 2014 EURETINA=European Society of Retina Specialists 105

Lebrikizumab (RG3637) Humanized monoclonal antibody designed to bind specifically to IL-13 Severe uncontrolled adult asthma Indication Adult patients whose asthma is uncontrolled with inhaled corticosteroids and a second controller medication Phase/study # of patients Design Phase III LAVOLTA I N=1,050 Subcutaneous lebrikizumab q4w on top of SOC for 52 weeks safety follow-up ARM A: lebrikizumab high dose ARM B: lebrikizumab low dose ARM C: placebo Patients will be tested for periostin level Phase III LAVOLTA II N=1,050 Subcutaneous lebrikizumab q4w on top of SOC for 52 weeks safety follow-up ARM A: lebrikizumab high dose ARM B: lebrikizumab low dose ARM C: placebo Patients will be tested for periostin level Primary endpoint Rate of asthma exacerbations during the 52-week placebo-controlled period Rate of asthma exacerbations during the 52-week placebo-controlled period Status Enrolment completed Q4 2014 Primary endpoint met Q1 2016 Enrolment completed Q4 2014 Primary endpoint not met Q1 2016 Further steps under discussion 106

Lebrikizumab (RG3637) Humanized monoclonal antibody designed to bind specifically to IL-13 (continued) Indication Phase/study Adolescent patients whose asthma is uncontrolled with inhaled corticosteroids and a second controller medication Phase III ACOUSTICS Idiopathic pulmonary fibrosis Phase II RIFF # of patients N=375 N=480 Design Primary endpoint Subcutaneous lebrikizumab q4w on top of SOC for 52 weeks with 52 week double-blind active treatment extension ARM A: lebrikizumab high dose, week 1-104 or week 52-104 ARM B: lebrikizumab low dose, week 1-104 or week 52-104 ARM C: placebo, week 1-52 Rate of asthma exacerbations during the 52- week placebo-controlled period ARM A: lebrikizumab SC q4w ARM B: placebo ARM C: lebrikizumab SC q4w + Esbriet ARM D: Esbriet Change in FVC at week 52 Status FPI Q3 2013 FPI Q4 2013 (arms A&B) FPI in Esbriet arms in Q3 2015 SOC=Standard of Care; OCS=Oral Corticosteroids 107

Lebrikizumab (RG3637) Humanized monoclonal antibody designed to bind specifically to IL-13 (continued) Indication Adult asthma Adult asthma mild to moderate patients Adult asthma Phase/study Phase II VOCALS Phase III STRETTO Phase II CLAVIER Mechanistic biomarker study # of patients N=225 N=300 N=120 Design ARM A: lebrikizumab high dose SC q4w ARM B: lebrikizumab low dose SC q4w ARM C: placebo ARM A: lebrikizumab SC q4w ARM B: placebo ARM C: Montelukast ARM A: lebrikizumab SC q4w ARM B: placebo Primary endpoint Relative change in OCS dose at week 44 Absolute change in FEV1 at week 12 Relative change in airway inflammation (eosinophils/mm2) at week 12 Status FPI Q1 2014 Recruitment completed Q3 2015 Data expected in 2016 FPI Q4 2014 OCS=Oral Corticosteroids 108

Lebrikizumab (RG3637) Humanized monoclonal antibody designed to bind specifically to IL-13 (continued) Indication Phase/stud y # of patients Design Moderate to severe atopic dermatitis Phase II TREBLE Phase II ARBAN Safety Study Moderate to very severe COPD Phase II VALETA N=200 N=50 N=300 Patients on topical corticosteroids ARM A: lebrikizumab dose 1 ARM B: lebrikizumab dose 2 ARM C: lebrikizumab dose 3 ARM D: placebo ARM A: lebrikizumab ARM B: topical corticosteroids Patients on background SOC during study ARM A: lebrikizumab SC q4w ARM B: placebo Primary endpoint Percentage of patients achieving a 50% reduction in Eczema Area and Severity Index (EASI) score (EASI-50) from baseline to week 12 Status Enrolment completed Q4 2015 Data expected in 2016 Safety comparison of lebrikizumab vs. TCS Enrolment completed Q4 2015 Data expected in 2016 Week 24 change from baseline in pre-bronchodilator forced expiratory volume (FEV-1) FPI Q3 2015 TCS=topical corticosteroids 109

Ocrevus (ocrelizumab, RG1594) Humanized monoclonal antibody designed to selectively target CD20-positive B cells Indication Relapsing multiple sclerosis (RMS) Primary-progressive multiple sclerosis (PPMS) Phase/study Phase III OPERA I Phase III OPERA II Phase III ORATORIO # of patients N=821 N=835 N=732 Design 96-week treatment period: ARM A: Ocrelizumab 2x 300 mg iv followed by 600 mg iv every 24 weeks ARM B: Interferon -1a 96-week treatment period: ARM A: Ocrelizumab 2x 300 mg iv followed by 600 mg iv every 24 weeks ARM B: Interferon -1a 120-week treatment period: ARM A: Ocrelizumab 2x 300 mg iv every 24 weeks ARM B: Placebo Primary endpoint Annualized relapse rate at 96 weeks versus Rebif Annualized relapse rate at 96 weeks versus Rebif Sustained disability progression versus placebo by Expanded Disability Status Scale (EDSS) Status Primary endpoint met Q2 2015 Data presented at ECTRIMS 2015 Expect global filing in 2016 Primary endpoint met Q2 2015 Data presented at ECTRIMS 2015 Expect global filing in 2016 Primary endpoint met Q3 2015 Data presented at ECTRIMS 2015 Expect global filing in 2016 ECTRIMS-European Committee for Treatment and Research in Multiple Sclerosis 110

Olesoxime (RG6083) Novel small molecule neuroprotectant that preserves mitochondrial function Indication Spinal muscular atrophy Phase/study Phase II Registrational study Open label study # of patients N=165 N=165 Design ARM A: olesoxime ARM B: placebo Olesoxime Primary endpoint Motor function measure Motor function measure Status Study completed Q4 2013 Presented at AAN 2014 Collaborator FPI Q4 2015 Trophos acquisition AAN=annual meeting of the American Academy of Neurology 111

Pipeline summary Marketed products additional indications Global Development late-stage trials pred (Roche Pharma Research & Early Development) gred (Genentech Research & Early Development) Roche Group Q1 2016 sales Diagnostics Foreign exchange rate information 112

Oncology development programmes Small molecules Molecule Idasanutlin (MDM2 antagonist, RG7388) Indication Relapsed or refractory acute myeloid leukemia Relapsed or refractory FL and DLBCL Relapsed or refractory AML not eligible for cytotoxic therapy Phase Phase III Phase Ib/II Phase I # of patients Design Primary endpoint N=440 N=116 N=140 ARM A: Idasanutin plus cytarabine ARM B: placebo plus cytarabine Dose escalation of idasanutlin plus Gazyva ARM A: Dose expansion of idasanutlin plus Gazyva in FL ARM B: Dose expansion of idasanutlin plus Gazyva in DLBCL Phase I (dose escalation) ARM A: Cotellic plus Venclexta ARM B: idasanutlin plus Venclexta Phase II (expansion) ARM A: Cotellic plus Venclexta ARM B: idasanutlin plus Venclexta Overall survival Safety and efficacy Safety and efficacy Status FPI Q4 2015 FPI Q4 2015 FPI Q1 2016 113

Oncology development programmes Small molecules Molecule Indication MDM2 antagonist IV prodrug (RG7775) Advanced cancers including AML LSD1 inhibitor (RG6016) Acute Leukemia Phase Phase I Phase I # of patients N=90 N=37 Design Dose-escalation study ARM A: patients with advanced solid tumours ARM B: patients with r/r AML Multiple ascending doseescalation study Primary endpoint MTD Safety, efficacy and PK Status FPI Q2 2014 FPI Q1 2014 Extension in MLL-AML initiated Q3 2015 Collaborator Oryzon Genomics, S.A. 114

Oncology development programmes Small molecules Molecule BET inhibitor (RG6146, TEN-010) Raf/MEK inhibitor (RG7304, CKI27) HIF1 alpha LNA (RG6061) Indication Solid tumors Acute Leukemia Solid tumours Hepatocellular carcinoma (HCC) Phase Phase I Phase I Phase I Phase I # of patients N=100 N=89 N=52 N=12 Design Dose escalation and expansion study Dose escalation and cohort expansion study Dose-escalation to MTD RG6061, 13 mg/kg/week, 2-hour IV infusion every week in a 6-week cycle, after two loading doses in week 1 of cycle 1 on day 1 and day 4 Primary endpoint Safety and efficacy Safety and efficacy MTD and tumour assessment Change from baseline to week 6 in HIF1A mrna level in tumour tissue Status FPI Q4 2013 FPI Q4 2014 Initiated Q4 2008 Enrolment stopped in Q4 2010 FPI Q1 2016 Collaborator Tensha acquisition Chugai Santaris acquisition 115

Oncology development programmes Monoclonal antibodies Molecule Indication Metastatic liver cancer (hepatocellular carcinoma) Codrituzumab (Glypican-3 MAb, GC33, RG7686) 2L metastatic liver cancer (hepatocellular carcinoma) Phase Phase Ib Phase II # of patients N= 40-50 N=185 Design Primary endpoint Study US monotherapy Study Japan monotherapy Dose escalation study in combo with SOC Safety and tolerability Adaptive design study Double blind randomized 2:1 RG7686: placebo Patients are stratified according to the level of GPC-3 expression in tumour Progression-free survival Status Recruitment completed Q4 2013 Data presented at ASCO 2014 Further steps under evaluation Recruitment completed Q1 2013 Data presented at ASCO 2014 Further steps under evaluation Collaborator Chugai SOC=standard of care; ASCO=American Society of Clinical Oncology 116

Oncology development programmes Monoclonal antibodies (continued) Molecule Vanucizumab (ANG2-VEGF bimab, RG7221) Indication Solid tumours Metastatic colorectal cancer Solid tumours Phase Phase I Phase II McCAVE Phase I # of patients N 160 N=190 N=170 Design Multiple ascending dose study with extension cohorts in solid tumours to assess the PD effects and platinum-resistant ovarian cancer Dose escalation of vanucizumab plus atezolizumab (PD-L1 MAb) ARM A: Induction: Avastin+mFOLFOX-6; followed by maintenance: Avastin+5-FU/LV ARM B: Induction: RG7221+mFOLFOX-6; followed by maintenance: RG7221+5- FU/LV Vanucizumab in combination with RG7876 (CD40 MAb) Primary endpoint Safety, PK Progression-free survival Safety, PD, efficacy Status FPI Q4 2012 Dose escalation data presented at ASCO 2014 Ovarian cancer cohort data presented at ASCO 2015 Biomarker/imaging data presented at ECC 2015 Expect FPI in combination arm in Q2 2016 Recruitment completed Q1 2015 Data expected in 2016 FPI Q1 2016 ASCO=American Society of Clinical Oncology; ECC=European Cancer Congress 117

Oncology development programmes Monoclonal antibodies (continued) Molecule Emactuzumab (CSF-1R MAb, RG7155) Cergutuzumab amunaleukin (CEA-IL2v, RG7813) Indication Solid tumours Solid tumours Solid tumours Solid tumours Phase Phase I/II Phase I Phase I Phase Ib # of patients N=216 N=110 N=113 N=75 Design Multiple ascending dose study +/- paclitaxel with extension cohorts RG7155 in combination with atezolizumab (PD-L1 MAb) Part 1: dose escalation Part 2: expansion Single and multiple dose escalation study with extension cohorts Part 1: dose escalation of RG7813 in combination with atezolizumab (PD-L1 MAb) Part 2: dose expansion RG7813 in combination with atezolizumab (PD-L1 MAb) Primary endpoint Safety, PK, PD & preliminary clinical activity Status FPI Q4 2011 Biomarker data presented at AACR 2013 and AACR 2014 Data presented at ASCO 2014 Updated data presented at ASCO 2015 Recruitment completed Q1 2016 Safety Safety, PK, PD Safety, Efficacy, PK, PD FPI Q1 2015 Recruitment completed Q1 2016 Imaging data presented at ASCO 2015 Biomarker/imaging data presented at ECC 2015 FPI in Q2 2015 AACR=American Association for Cancer Research; ASCO=American Society of Clinical Oncology; ECC=European Cancer Congress 118

Oncology development programmes Monoclonal antibodies (continued) Molecule CEA CD3 T-cell bispecific (TCB) (RG7802) CD40 MAb (RG7876) Indication CEA-positive solid tumours Solid tumours Solid tumours Phase Phase Ia Phase I Phase I Phase I # of patients N=90 N=100 N=160 N=170 Design Multiple ascending dose study with MTD/OBD expansion cohorts RG7802 plus atezolizumab (PD-L1 MAb) Part I: RG7876 single dose escalation in combination with atezolizumab (PD-L1 MAb) Part II: RG7876 multiple doses in combination with atezolizumab Part III: indication specific extension RG7876 dose escalation in combination with vanucizumab (ANG2-VEGF bimab) Primary endpoint Safety, PK, PD, imaging, BM Safety, PK/PD, imaging, biomarkers Safety, PD, efficacy Safety, PD, efficacy Status FPI Q4 2014 FPI Q1 2016 FPI Q4 2014 FPI Q1 2016 119

Oncology development programmes Monoclonal antibodies (continued) Molecule FAP-DR5 bimab (RG7386) FAP-IL2v FP (RG7461) Indication Solid tumours Solid tumours Phase Phase I Phase I # of patients N=120 N=60 Design Part I: Dose escalation Part II: tumour biopsy and imaging evaluation for assessment of treatment-induced pharmacodynamic (PD) effects Part III: Evaluation of anti-tumour activity of single agent RO6874813 patients with histologically confirmed recurrent or metastatic, non-resectable FAP+ sarcomas with two or fewer prior regimens for advanced disease Dose escalation study Primary endpoint Parts I & II safety and tolerability Part III antitumour activity Safety, PK/PD Status FPI Q3 2015 FPI Q4 2015 120

Neuroscience development programmes Molecule Basmisanil (GABRA5 NAM, RG1662) Indication Down syndrome Down syndrome, children 6 11 years of age Phase Phase IIB CLEMATIS Phase II # of patients N=169 N=46 Design For 26 weeks patients will receive: ARM A: RG1662 120mg twice daily ARM B: RG1662 120mg twice daily ARM C: Placebo For 26 weeks patients will receive 1 of 3 dosages of RG1662 PO BID: 40 mg, 60 mg, or 120 mg Primary endpoint Cognition and adaptive behavior PK, PD, efficacy, safety, and tolerability Status Recruitment completed Q4 2015 Data expected in 2016 FPI Q4 2015 NAM=Negative allosteric modulator 121

Neuroscience development programmes Molecule NME (RG7906) PDE10A inhibitor (RG7203) Indication Psychiatric disorders Schizophrenia Phase Phase I Phase I # of patients N=164 N=26 Design Primary endpoint Part 1:adaptive single ascending dose in HVs. Single-center, randomized, placebo-controlled, parallel study Part 2: adaptive multiple ascending dose in HVs. Single-center, randomized, Investigator/subject/blind, placebo-controlled, parallel study Safety, tolerability, PK, PD Randomized, double-blinded, placebocontrolled study of multiple doses of RG7203 administered orally to psychiatrically stable patients with schizophrenia receiving risperidone ARM A: RG7203 plus risperidone ARM B: placebo plus risperidone Safety, tolerability, PK Status FPI Q1 2016 Study completed Q3 2014 Next study in preparation 122

Neuroscience development programmes (continued) Molecule SMN2 splicing modifier (RG7800) SMN2 (2) splicing modifier (RG7916) Indication Spinal muscular atrophy Spinal muscular atrophy Phase Phase Ib MOONFISH Phase I # of patients N=48 N=93 Design Primary endpoint Status Randomized, double-blind, 12-week, placebocontrolled multiple dose study in adult and pediatric patients Safety and tolerability Study on hold First cohort completed Healthy volunteer data presented at AAN and CureSMA 2015 SMA patient data from first cohort presented at WMS 2015 Randomized, double-blind, adaptive singleascending-dose (SAD), placebo-controlled study Safety and tolerability FPI Q1 2016 Collaborator PTC Therapeutics/ SMA Foundation AAN=American Academy of Neurology; WMS=World Muscle Society 123

Neuroscience development programmes (continued) Molecule V1 receptor antagonist (RG7314) Anti-αSynuclein (RG7935, PRX002) Indication Autism Parkinson s disease Phase Phase II VANILLA Phase I Phase I # of patients N=225 N=40 N=up to 80 Design Multi-center, randomized, double-blind, placebo-controlled proof-of-concept study in individuals with Autism Spectrum Disorder (ASD) Double-blind, placebo-controlled, single, ascending dose study of RG7935 in healthy subjects Double-blind, placebo-controlled, multiple ascending dose study of RG7935 in patients with Parkinson s disease Primary endpoint Safety and efficacy Safety, tolerability and PK Safety and tolerability Status FPI Q3 2013 Study completed Q1 2015 Data presented at MDS 2015 FPI Q3 2014 Collaborator Prothena ECNP=European College of Neuropsychopharmacology; ACNP=American College of Neuropsychopharmacology ASCP=American Society of Clinical Phsycopharmacology; MDS=Movement Disorder Society 124

Infectious diseases development programmes Molecule DBO beta lactamase inhibitor (RG6080) TLR7 agonist (RG7795) HBV therapeutic vaccine (RG7944, INO-1800 and INO-9112)) NME (RG7834) Indication Infectious diseases Chronic hepatitis B Chronic hepatitis B Chronic hepatitis B Phase Phase I Phase II Phase I Phase I # of patients N=40 N=40 N=126 N=165 Design Randomized, doubleblind, placebo-controlled, single-ascending dose study in healthy volunteers Various doses of RG7795 vs. placebo INO-1800, alone or in combination with INO- 9112 Healthy volunteer and chronic hepatitis B patient study Primary endpoint Safety, PK Safety, efficacy Safety, tolerability and immunogenicity Safety, PK/PD Status Study completed FPI Q2 2015 FPI Q2 2015 FPI Q4 2015 Collaborator Meiji and Fedora Inovio 125

Ophthalmology development programmes Molecule VEGF-Ang2 bimab (RG7716) NME (RG4929) Indication Wet age-related macular degeneration Center-involving diabetic macular edema (CI-DME) Primary open angle glaucoma (POAG) or ocular hypertension (OHT) Phase/study Phase II AVENUE Phase II BOULEVARD Phase I # of patients N=271 N=150 N=60 Design Arm A: SoC (Lucentis, q4w Arm B: 1.5 mg VA2, q4w Arm C: 6mg VA2, q4w / q8w Arm E: Soc q4w x 3 doses, switch group to 6 mg VA2 q4w Arm A: SOC (Lucentis ).3 mg), q4w Arm B: 1.5mg VA2, q4w Arm C: 6 mg VA2, q4w Part 1: ARM A: multiple ascending doses of RG4929 ARM B: placebo Part 2: ARM A: RG4929 ARM B: Latanoprost Primary endpoint Visual acuity (change in BCVA) after 32 weeks Mean change from baseline in BCVA at week 24 Safety and efficacy Status FPI Q3 2015 Expect FPI Q2 2016 FPI Q4 2015 126

Immunology development programmes Molecule Cathepsin S inhibitor (RG7625) Indication Primary Sjögren s syndrome Celiac disease Phase/study Phase II Phase I # of patients N=70 N=22 Design Arm A: RG7625 Arm B: placebo Arm A: RG7625 Arm B: placebo Primary endpoint Percentage of participants with a Clinically Relevant Decrease in European League Against Rheumatism (EULAR) Sjoören s Syndrome Disease Activity Index (ESSDAI) Score Status Expect FPI Q2 2016 FPI Q1 2016 Overall numbers of participants who are Responders to the gluten challenge 127

Pipeline summary Marketed products additional indications Global Development late-stage trials pred (Roche Pharma Research & Early Development) gred (Genentech Research & Early Development) Roche Group Q1 2016 sales Diagnostics Foreign exchange rate information 128

Oncology development programmes Monoclonal antibodies Molecule OX40 MAb (RG7888, MOXR0916) CD20/CD3 bimab (RG7828) Indication Solid tumours Solid tumours Hematologic tumours Phase Phase I Phase I Phase I # of patients N=400 N=360 N=170 Design RG7888 dose escalation and expansion study RG7888 plus atezolizumab (PD-L1 MAb) dose escalation and expansion Dose escalation and expansion Primary endpoint Safety Safety Safety, PK/PD Status FPI Q3 2014 Dose escalation data to be presented at AACR 2016 FPI Q2 2015 Dose escalation data to be presented at ASCO 2016 FPI Q3 2015 AACR=American Association for Cancer Research ; ASCO=American Society of Clinical Oncology 129

Oncology development programmes Antibody-drug conjugates Molecule NME ADC (RG7882) Ly6E ADC (RG7841) NME ADC (RG7986) Indication Pt-resistant ovarian cancer or unresectable pancreatic cancer HER2-neg. breast cancer and NSCLC Relapsed or refractory B cell non-hodgkin s lymphoma Phase Phase I Phase I Phase I # of patients N=95 N=115 N=80 Design Dose escalation and expansion study Dose escalation and expansion study Dose escalation and expansion Primary endpoint Safety/PK Safety Safety, PK Status FPI Q2 2014 FPI Q2 2014 Expansion study: FPI Q2 2015 FPI Q3 2015 Collaborator Seattle Genetics 130

Oncology development programmes Small molecules Molecule Indoleamine 2, 3-dioxygenase (IDO) Inhibitor (RG6078, GDC-0919, NLG919) Indication Solid tumours Solid tumours Phase Phase I Phase I # of patients N=36 N=224 Design Dose escalation study Dose escalation and expansion study of IDO and atezolizumab (PD-L1 MAb) combination Primary endpoint Safety Safety, tolerability, and PK Status FPI Q1 2014 Safety and PK/PD data presented at ECC 2015 FPI Q3 2015 Collaborator NewLink Genetics ECC=European Cancer Congress 131

Oncology development programmes Small molecules (continued) Molecule ChK1 inhibitor (RG7741,GDC-0575) ERK inhibitor (RG7842, GDC-0994) Indication Solid tumours Solid tumours Solid tumours Phase Phase I Phase I Phase I # of patients N=112 N=78 N=142 Design Stage 1: Dose escalation Stage 2: Cohort expansion Stage 1: Dose escalation Stage 2: Cohort expansion Dose escalation study of RG7842 and Cotellic (MEK inhibitor)* combination Primary endpoint Safety/PK Safety, MTD, PK Safety and tolerability Status FPI Q2 2012 FPI Q2 2013 FPI Q2 2015 Collaborator Array BioPharma *Cotellic in collaboration with Exelixis 132

Oncology development programmes Small molecules (continued) Molecule Selective estrogen receptor degrader (SERD) (RG6046, GDC-0810/ARN-810) Selective estrogen receptor degrader (SERD(2)) (RG6047, GDC-0927/SRN-927) Indication Metastatic ER+ HER2-neg. breast cancer Advanced or metastatic ER+ HER2- neg. breast cancer resistant to aromatase inhibitor therapy Metastatic ER+ HER2-neg. breast cancer Phase Phase I/IIa Phase II HydranGea Phase I # of patients N=177 N=152 N=90 Design Primary endpoint Phase I: dose escalation Phase IIa: dose expansion Phase Ib: RG6046 in combination with palbociclib Safety, PK, MTD Status FPI Q4 2014 Initial data presented at SABCS 2014 and AACR 2015 FPI in palbociclib arm Q1 2016 Collaborator ARM A: RG6046 Arm B: fulvestrant Progression-free survival in all participants and for subset of participants with estrogen receptor (ESR)1 mutations Dose escalation study Safety FPI Q4 2015 FPI Q1 2015 Seragon acquisition SABCS=San Antonio Breast Cancer Symposium; AACR=American Association for Cancer Research 133

Oncology development programmes Small molecules (continued) Molecule Ipatasertib (AKT inhibitor, RG7440, GDC-0068) Indication 2L castration-resistant prostate cancer 1L metastatic gastric or gastroesophageal junction adenocarcinoma 1L triple-negative breast cancer Phase Phase II A.MARTIN Phase II JAGUAR Phase II LOTUS # of patients N=262 N=153 N=120 Design ARM A: ipatasertib (400mg) + abiraterone ARM B: ipatasertib (200mg) + abiraterone ARM C: placebo + abiraterone ARM A: ipatasertib + mfolfox6 ARM B: placebo + mfolfox6 ARM A: ipatasertib + paclitaxel ARM B: placebo + paclitaxel Primary endpoint Progression-free survival Progression-free survival Progression-free survival Status Enrolment completed Q4 2014 Data in-house To be presented at ASCO 2016 Collaborator Enrolment completed Q4 2014 Data in-house Array BioPharma Recruitment completed Q1 2016 mfolfox6=modified FOLFOX (folinic acid, fluorouracil, oxaliplatin) 134

Oncology development programmes Small molecules (continued) Molecule Ipatasertib (AKT inhibitor, RG7440, GDC-0068) Indication Solid tumours Neoadjuvant TNBC Phase Phase Ib Phase II FAIRLANE # of patients N=120 N=150 Design Primary endpoint Dose escalation with: ARM A: docetaxel ARM B: fuoropyrimidine plus oxaliplatin ARM C: paclitaxel ARM D: enzalutamide Safety ARM A: ipatasertib + paclitaxel ARM B: placebo + paclitaxel Pathologic complete response (pcr) Status FPI Q3 2011 Data presented at ESMO and SABCS 2014 FPI Q1 2015 Collaborator Array BioPharma TNBC=triple-negative breast cancer; ESMO=European Society for Medical Oncology; SABCS=San Antonio Breast Cancer Symposium 135

Immunology development programmes Molecule IL22-Fc (RG7880) NME (RG6069, GDC-3280) BTKi (RG7845, GDC-0853) ST2 MAb (RG6149, AMG 282) Indication Inflammatory diseases Fibrosis Autoimmune diseases Asthma Phase Phase I Phase I Phase I Phase I # of patients N=48 N=88 N=123 N=96 Design Healthy volunteer study Randomized, double-blind, placebo-controlled, ascending, single and multiple oral dose study Primary endpoint Healthy volunteer single and multiple ascending dose study A randomized, doubleblind, placebo-controlled, ascending, single dose study in healthy subjects and subjects with mild atopic asthma Safety and tolerability Safety, tolerability, and PK Safety, tolerability, and PK Safety, tolerability, PK and PD Status FPI Q4 2014 Recruitment completed Q4 2015 Collaborator Last subject last visit Q4 2015 Favorable safety, PK and PD demonstrated Phase 2 study in rheumatoid arthritis to start in 2016 FPI Q3 2013 Amgen 136

Neuroscience development programmes Molecule Nav1.7 (RG7893, GDC-0276) Nav1.7 (2) (RG6029, GDC-0310) Indication Pain Pain NME (RG6000, GDC-0134) Amyotrophic lateral sclerosis Phase Phase I Phase I Phase I # of patients N=230 N=84 N=39 Design Randomized, placebocontrolled, double blinded study in healthy volunteers Randomized, placebocontrolled, double blinded study in healthy volunteers Randomised, double-blind, placebo-controlled, multicenter, single-ascending dose study Primary endpoint Safety, tolerability, and pharmacokinetics of single and multiple doses Safety, tolerability, and Safety, tolerability, PK of single pharmacokinetics of single and dose multiple doses Status FPI Q3 2014 FPI Q3 2015 Expect FPI Q2 2016 Collaborator Xenon Pharmaceuticals Inc. 137

Infectious diseases development programmes Molecule Flu A MAb (RG7745) Flu B MAb (RG6024) StaphA vcrifalog TAC (RG7861) Indication Influenza A Acute uncomplicated seasonal influenza A Influenza B Serious infections caused by Staphylococcus aureus Phase Phase IIb Phase II Phase I Phase I # of patients N~300 N=141 N=26 N=30 Design Hospitalized patients requiring oxygen with severe influenza A ARM A: RG7745 + Tamiflu ARM B: placebo + Tamiflu Arm A: RG7745 dose level 1 Arm B: RG7745 dose level 2 Arm C: placebo Randomized, double blind, placebo controlled, healthy volunteer, single ascending dose study Healthy volunteer study Primary endpoint Safety and efficacy (time to normalization of respiratory function) Safety Safety, tolerability, and PK Safety Status FPI Q1 2015 FPI Q1 2016 FPI Q3 2015 FPI Q4 2015 Collaborator Seattle Genetics and Symphogen TAC=THIOMAB antibiotic conjugate 138

Pipeline summary Marketed products additional indications Global Development late-stage trials pred (Roche Pharma Research & Early Development) gred (Genentech Research & Early Development) Roche Group Q1 2016 sales Diagnostics Foreign exchange rate information 139

Q1 2016: Geographical sales split by divisions and Group* CHFm Q1 2016 Q1 2015 % change CER Pharmaceuticals Division 9,800 9,322 +4 United States 4,716 4,392 +3 Europe 2,319 2,178 +5 Japan 853 763 +4 International 1,912 1,989 +4 Diagnostics Division 2,614 2,511 +5 United States 641 616 0 Europe 945 946-1 Japan 95 92-3 International 933 857 +16 Group 12,414 11,833 +4 United States 5,357 5,008 +3 Europe 3,264 3,124 +3 Japan 948 854 +3 International 2,845 2,847 +7 * Geographical sales split shown here does not represent operational organisation; CER=Constant Exchange Rates 140

Pharma Division sales Q1 2016 (vs. 2015) Top 20 products Global US Europe Japan International CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER MabThera/Rituxan 1,825 3 978 0 479 5 62 12 306 11 Herceptin 1,725 4 651 4 525 2 67 5 482 7 Avastin 1,706 4 775-2 471 2 192 7 268 27 Perjeta 439 33 224 15 149 65 23 18 43 65 Actemra/RoActemra 386 14 145 12 131 17 60 14 50 10 Tamiflu 367-6 251-15 20 78 60 4 36 35 Xolair 356 22 356 22 - - - - - - Lucentis 355-13 355-13 - - - - - - Activase/TNKase 276 21 265 21 - - - - 11 13 Tarceva 258-14 136-15 48-18 22 0 52-14 Kadcyla 201 11 79-2 83 13 17 27 22 56 Cellcept 189-4 45 0 43-3 15 11 86-8 Esbriet 178 96 127 145 45 36 - - 6 4 Pulmozyme 160 7 112 6 31 6 - - 17 22 Mircera 118 0 - - 21-7 45 4 52 0 Xeloda 111-17 5-71 9-31 25 12 72-13 Rocephin 82 5 - - 13-13 6-10 63 12 Pegasys 82-50 11-16 19-40 1-83 51-55 NeoRec./Epogin 79-14 - - 36-10 10-12 33-18 Valcyte / Cymevene 78-21 19-25 30-26 - - 29-14 CER=Constant Exchange Rates 141

Pharma Division sales Q1 2016 (vs. 2015) Recently launched products Global US Europe Japan International CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER Zelboraf 53-1 12-2 32-6 1 146 8 9 Erivedge 49 46 33 37 12 54 - - 4 104 Gazyva 45 67 29 67 11 162 - - 5-7 Alecensa 29 161 10 * - - 19 66 - - Cotellic 11 * 2 * 9 * - - - - CER=Constant Exchange Rates * over +500% 142

Pharma Division CER sales growth 1 in % Global top 20 products CER=Constant Exchange Rates 1 Q2-Q4/15 vs. Q2-Q4/14; Q1/16 vs. Q1/15 Q1/15 Q2/15 Q3/15 Q4/15 Q1/16 MabThera/Rituxan 5 6 4 4 3 Herceptin 12 10 7 10 4 Avastin 6 13 8 9 4 Perjeta 82 64 57 50 33 Actemra/RoActemra 27 23 18 25 14 Tamiflu 6 61 46-67 -6 Xolair 28 27 21 22 22 Lucentis -9-16 -18-17 -13 Activase/TNKase 15 16 14 36 21 Tarceva -3-10 -7-9 -14 Kadcyla 80 54 44 36 11 Cellcept -7-1 -4 13-4 Esbriet - - - 296 96 Pulmozyme 4 15 14 8 7 Mircera 17 17 55-1 0 Xeloda -53-29 -11-9 -17 Rocephin 18 0-8 -1 5 Pegasys -39-58 -45-32 -50 NeoRec./Epogin -10-19 -8-6 -14 Valcyte / Cymevene -41-47 -52-41 -21 143

Pharma Division CER sales growth 1 in % Top 20 products by region US Europe Japan International Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 MabThera/Rituxan 7 4 7 0-1 1 3 5 28 7 9 12 13 5-2 11 Herceptin 18 12 13 4-1 0 4 2 22 3 3 5 14 9 16 7 Avastin 11 6 11-2 4 5 5 2 29 13 12 7 27 16 7 27 Perjeta 43 37 31 15 125 96 74 65 21 18 14 18 112 125 131 65 Actemra/RoActemra 30 21 32 12 21 19 23 17 28 13 10 14 8 15 31 10 Tamiflu 131 54-74 -15 478-65 455 78-97 -96-75 4 18 22 73 35 Xolair 27 21 22 22 - - - - - - - - - - - - Lucentis -16-18 -17-13 - - - - - - - - - - - - Activase/TNKase 18 15 36 21 - - - - - - - - -10-11 32 13 Tarceva -15-7 1-15 -16-20 -23-18 8 12-1 0 6-1 -18-14 Kadcyla -2 6 12-2 135 92 49 13 81 39 23 27 131 74 93 56 Cellcept 2-14 29 0-9 -10-1 -3 8 11 11 11 1 5 16-8 Esbriet - - * 145 - - 44 36 - - - - - - 114 4 Pulmozyme 15 9 19 6 2 8 8 6 - - - - 34 49-22 22 Mircera - - - - -3-1 -4-7 23 6 9 4 24 206-13 0 Xeloda -48 3 13-71 -53-41 -30-31 22 8 10 12-27 -11-12 -13 Rocephin - - - - -8-15 -27-13 1-2 -5-10 2-7 0 12 Pegasys -84-45 74-16 -58-45 -45-40 -73-82 -84-83 -42-40 -42-55 NeoRec./Epogin - - - - -11-9 -6-10 0-7 -9-12 -29-8 -5-18 Valcyte / Cymevene -83-86 -64-25 -8-1 -16-26 - - - - -1-17 -22-14 CER=Constant Exchange Rates * over 500% 1 Q2-Q4/15 vs. Q2-Q4/14; Q1/16 vs. Q1/15 144

CER sales growth (%) Quarterly development 2015 vs. 2014 2016 vs. 2015 Q1 Q2 Q3 Q4 Q1 Pharmaceuticals Division 4 7 6 3 4 United States 6 7 7 3 3 Europe 1 3 6 5 5 Japan -2 18 8 2 4 International 9 5 4 2 4 Diagnostics Division 6 7 4 7 5 Roche Group 5 7 6 4 4 CER=Constant Exchange Rates 145

MabThera/Rituxan CHFbn 2.0 Global sales CER growth +3% Regional sales CER growth US 0% 1.5 Europe +5% 1.0 Japan +12% 0.5 International +11% 0.0 Q1 12 Q1 13 Q1 14 Q1 15 Q1 16 Q1 2016 sales of CHF 1,825m Immunology sales grew +11% (driven by the US in RA and GPA/MPA) Oncology sales grew +1% International: Growth driven by China (reimbursement obtained) CER=Constant Exchange Rates 146

Herceptin CHFbn 2.0 Global sales CER growth +4% Regional sales CER growth US +4% 1.5 Europe +2% 1.0 Japan +5% 0.5 International +7% 0.0 Q1 12 Q1 13 Q1 14 Q1 15 Q1 16 Q1 2016 sales of CHF 1,725m US: Strong volume momentum in 1L mbc due to longer treatment times EU: Solid volume momentum with switching to the subcutaneous formulation on-going International: Strong growth remains driven by APAC (China) CER=Constant Exchange Rates 147

Avastin CHFbn 2.0 Global sales CER growth +4% Regional sales CER growth US -2% 1.5 Europe +2% 1.0 Japan +7% 0.5 International +27% 0.0 Q1 12 Q1 13 Q1 14 Q1 15 Q1 16 Q1 2016 sales of CHF 1,706m US: Solid underlying growth (ovarian and cervical cancer); Negative impact from buying patterns EU: Slight growth driven by ovarian cancer and cervical cancer International: Growth driven by LATAM and China (NSCLC launch gaining traction) Japan: Strong underlying growth; Negative impact from a one-time -11% price cut (April 1 rst ) CER=Constant Exchange Rates 148

Perjeta CHFbn 0.5 Global sales CER growth +33% Regional sales CER growth US +15% 0.4 Europe +65% 0.3 0.2 Japan +18% 0.1 International +65% 0.0 Q1 12 Q1 13 Q1 14 Q1 15 Q1 16 Q1 2016 sales of CHF 439m US: Growth driven by 1L mbc and neoadjuvant (further increase in new patient share) EU: Growth driven by 1L mbc and momentum in neoadjuvant (approval in Q3 `15) International: Strong growth in all regions CER=Constant Exchange Rates 149

Actemra/RoActemra CHFbn 0.4 Global sales CER growth +14% Regional sales CER growth US +12% 0.3 Europe +17% 0.2 Japan +14% 0.1 International +10% 0.0 Q1 12 Q1 13 Q1 14 Q1 15 Q1 16 Q1 2016 sales of CHF 386m US: Growth driven by continued SC uptake and increased monotherapy share EU: Growth driven by further strengthening market leadership in monotherapy and SC adoption CER=Constant Exchange Rates 150

Xolair CHFbn 0.4 Global sales CER growth +22% Regional sales CER growth 0.3 US +22% 0.2 0.1 0.0 Q1 12 Q1 13 Q1 14 Q1 15 Q1 16 Q1 2016 sales of CHF 356m Growth driven by strong uptake in allergic asthma and chronic idiopathic urticaria (CIU) Positve growth outlook for 2016 supported by pediatric launch CER=Constant Exchange Rates 151

Tarceva CHFbn 0.4 Global sales CER growth -14% Regional sales CER growth US -15% Europe -18% 0.3 Japan 0% 0.2 International -14% 0.1 0.0 Q1 12 Q1 13 Q1 14 Q1 15 Q1 16 Q1 2016 sales of CHF 258m Continued decline due to in-class competition (1L EGFR Mut+ NSCLC and 2/3L EGFR WT NSCLC) and out-of-class competition from immunotherapies (2L WT NSCLC) EU: Avastin + Tarceva filed in 1L EGFR+ NSCLC CER=Constant Exchange Rates 152

Kadcyla CHFbn 0.3 Global sales CER growth +11% Regional sales CER growth US -2% Europe +13% 0.2 0.1 Japan +27% International +56% 0.0 Q1 12 Q1 13 Q1 14 Q1 15 Q1 16 Q1 2016 sales of CHF 201m Patient shares in 2L mbc above 60% in the US and EU Europe: Strong uptake in recently launched countries (e.g. Italy and France) International: Growth driven by all regions; Reimbursement negotiations on-going CER=Constant Exchange Rates 153

Esbriet CHFbn 0.2 Global sales CER growth +96% Regional sales CER growth US +145% Europe +36% 0.1 International +4% 0.0 Q1 12 Q1 13 Q1 14 Q1 15 Q1 16 Q1 2016 sales of CHF 178m Market leadership established in the US and EU US: Strong underlying growth with the run-rate of new patients being on track Steady growth expected going forward CER=Constant Exchange Rates 154

Lucentis CHFbn 0.5 Global sales CER growth -13% Regional sales CER growth 0.4 US -13% 0.3 0.2 0.1 0.0 Q1 12 Q1 13 Q1 14 Q1 15 Q1 16 Q1 2016 sales of CHF 355m US: In-class competition in wamd and DME continuing Protocol T 2Y follow-up in DME shows no statistical difference in visual outcomes, number of injections and visits between Lucentis and competitors wamd=wet age-related macular degeneration; DME=diabetic macular edema CER=Constant Exchange Rates 155

Tamiflu quarterly sales 2012-2016 Retail and Governments/Corporations 600 Retail Governments & Corporations 500 400 300 496 200 288 302 277 376 356 100 0 214 177 44 26 32 15 10 8 5 31 33 1 2 7 67 139 17 70 39 111 11 10 11 0 2 7 31 11-100 Q1 12 Q2 12 Q3 12 Q4 12 Q1 13 Q2 13 Q3 13 Q4 13 Q1 14 Q2 14 Q3 14 Q4 14 Q1 15 Q2 15 Q3 15 Q4 15 Q1 16 156

Total number of countries Sales market share (%) Herceptin SC launched in 51* countries Conversion rate at 41% Number of countries where Herceptin SC has been launched (ex Arg, Mex, HKG) SC share of Herceptin sales in launched countries (ex Arg, Mex, HKG) 60 50 40 48 45% 40% 35% 30% 41% 30 20 25% 20% 15% 10 0 Q2 13 Q3 13 Q4 13 Q1 14 Q2 14 Q3 14 Q4 14 Q1 15 Q2 15 Q3 15 Q4 15 Q1 16 10% 5% 0% Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 13 13 13 14 14 14 14 15 15 15 15 16 * Sales recorded in 51 countries YTD; Charts are showing sales without Argentina, Mexico and Hong Kong, where Herceptin SC was launched only in Q1/16 157

Development plan: Lebrikizumab Read-outs in AD and IPF monotherapy expected 2015 2016 2017 2018 Severe uncontrolled asthma Adults High dose/low dose Q4W LAVOLTA I/II Mixed results Mild to moderate asthma Adults STRETTO Severe uncontrolled asthma Adolescents High/low dose Q4W ACOUSTICS Asthma Adults (OCS-sparing) High/low dose Q4W VOCALS Asthma Biomarker CLAVIER IPF Mono and lebrikizumab+esbriet RIFF Moderate to severe atopic dermatitis Moderate to severe atopic dermatitis TREBLE ARBAN Phase I Phase II COPD VALETA Phase III Q4W=monthly dosing; PK=pharmacokinetic study; AD=atopic dermatitis; IPF=idiopathic pulmonary fibrosis; COPD=chronic obstructiv pulmonary disease; OCS=oral corticosteroid 158

Pipeline summary Marketed products additional indications Global Development late-stage trials pred (Roche Pharma Research & Early Development) gred (Genentech Research & Early Development) Roche Group Q1 2016 sales Diagnostics Foreign exchange rate information 159

Q1 2016: Diagnostics Division CER growth By Region and Business Area (vs. 2015) Global North America EMEA¹ RoW % CER % CER % CER % CER CHFm growth CHFm growth CHFm growth CHFm growth Professional Diagnostics 1,519 7 348 4 626 3 545 15 Diabetes Care 443-11 48-49 285-6 110 11 Molecular Diagnostics 446 11 182 10 166 8 98 20 Tissue Diagnostics 206 13 125 14 53 9 28 13 Diagnostics Division 2,614 5 703 0 1,130 1 781 15 CER=Constant Exchange Rates ¹ Europe, Middle East and Africa 160

Diagnostics Division quarterly sales and CER growth 1 Q4 14 Q1 15 CHFm % CER CHFm % CER Q2 15 Q3 15 Q4 15 CHFm % CER CHFm % CER CHFm % CER Q1 16 CHFm % CER Professional 1,648 8 1,425 6 1,547 8 1,515 7 1,688 9 1,519 7 Diagnostics Diabetes 671 1 507 1 550 0 476-9 595-3 443-11 Care Molecular 448 7 401 10 431 14 416 8 471 9 446 11 Diagnostics Tissue 207 10 178 14 196 11 193 11 225 10 206 13 Diagnostics Dia Division 2,974 7 2,511 6 2,724 7 2,600 4 2,979 7 2,614 5 CER=Constant Exchange Rates ¹ versus same period of prior year 161

Q1 2016: Diagnostics Division sales Growth driven by Asia Pacific CHF 2,614 m CER sales growth 703 North America 27% Diagnostics Division 5% 529 Asia Pacific 20% EMEA¹ North America 1% 0% Asia Pacific 16% 1,130 95 157 Latin America Japan EMEA 1 6% 4% 43% Latin America Japan -3% 21% CER=Constant Exchange Rates 1 Europe, Middle East and Africa 162

Q1 2016: Diagnostics Division sales Growth driven by Professional Diagnostics CHF 2,614 m CER sales growth 443 Diabetes Care 17% Dia Division 5% 446 Molecular Diagnostics 17% Professional Diagnostics Diabetes Care -11% 7% 1,519 206 Tissue Diagnostics 8% Molecular Diagnostics 11% Professional Diagnostics 58% Tissue Diagnostics 13% CER=Constant Exchange Rates 163

Professional Diagnostics CHFbn 1.6 1.2 0.8 2016 vs. 2015 CER growth +7% +1% 0% +6% 0.4 +12% 0.0 Q1 14 Q1 15 Q1 16 Immunodiagnostics Clinical Chemistry POC products Other CER=Constant Exchange Rates 164

Diabetes Care CHFbn 0.6 2016 vs. 2015 CER growth -11% 0.5 0.4 0.3 0.2-3% -12% 0.1 0.0 Q1 14 Q1 15 Q1 16 Blood Glucose Monitoring Other CER=Constant Exchange Rates 165

Molecular Diagnostics CHFbn 0.5 2016 vs. 2015 CER growth +11% 0.4 0.3 0.2 0.1 +43% +7% -3% -8% +16% 0.0 Q1 14 Q1 15 Q1 16 Other HPV & Microbiology Blood Screening Biochem Reag & qpcr & NAP Systems Virology CER=Constant Exchange Rates 166

Tissue Diagnostics CHFbn 0.3 2016 vs. 2015 CER growth +13% 0.2 +3% +24% +29% 0.1 +10% 0.0 CER=Constant Exchange Rates Q1 14 Q1 15 Q1 16 Advanced Staining Companion Dia Primary Staining Digit Path&Workflow 167

2016: Key planned product launches Professional Diagnostics Product Description Region cobas c 513 dedicated HbA1C analyzer US cobas e801 high throughput immunochemistry analyzer EU CoaguChek INRange (Zenith) Modified analyzer for intuitive self testing with full blue tooth connectivity EU Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors 168

2016: Key planned product launches Molecular Diagnostics Product Description Region cobas 6800/8800 HIV Qual cobas 6800/8800 CT/NG cobas Liat Influenza A/B + RSV (CLIA) early infant diagnosis and confirmatory HIV test fully automated solution for screening and diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae in symptomatic & asymptomatic patients automated multiplex real time RT-PCR assay for qualitative detection and discrimination of Influenza A virus, Influenza B virus and respiratory syncytial virus (RSV) EU EU US Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors 169

2016: Key planned product launches Tissue Diagnostics Product Description Region Companion Diagnostics PD-L1 (SP142) for Bladder Cancer* companion diagnostic for atezolizumab PD-L1 (SP142) for NSCLC* companion diagnostic for atezolizumab US Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors 170

2016: Key planned product launches Sequencing Product Description Region Roche SMRT sequencer ctdna oncology panels single molecule sequencer for clinical research (in collaboration with Pacific Biosciences) liquid biopsy for circulating tumor DNA for cancer therapy selection WW US Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors 171

2016: Key planned product launches Diabetes Care Product Description Region Accu-Chek Guide next-gen. bg monitoring system EU Accu-Chek Insight CGM new high-performance continuous glucose monitoring system EU Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors 172

Pipeline summary Marketed products additional indications Global Development late-stage trials pred (Roche Pharma Research & Early Development) gred (Genentech Research & Early Development) Roche Group Q1 2016 sales Diagnostics Foreign exchange rate information 173

CHF / USD 1.03 1.01 0.99 0.97 0.95 0.93 0.91 Monthly averages 2016 2015 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Year-To-Date averages 1.03 1.01 0.99 0.97 2016 +4% 0.95 0.93 0.91 2015 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 174

CHF / USD 1.03 1.01 0.99 0.97 monthly avg 2016 +3% Q1 2016 avg monthly avg 2015 0.95 avg full year 2015 0.93 0.91 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 175

CHF / EUR 1.12 1.10 1.08 1.06 1.04 1.02 Monthly averages 2016 2015 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Year-To-Date averages 1.12 2016 1.10 1.08 1.06 2015 +2% 1.04 1.02 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 176

CHF / EUR 1.12 monthly avg 2016 1.10 Q1 2016 avg 1.08 +3% 1.06 avg full year 2015 1.04 monthly avg 2015 1.02 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 177

Average exchange rates Q1 2016 Q1 2015 Q1 2016 vs. Q1 2015 USD 0.99 0.95 4% EUR 1.10 1.08 2% JPY 0.86 0.80 8% -10% -5% 0% 5% 10% 178

Exchange rate impact on sales growth In Q1 2016 positive impact of three main currencies Development of average exchange rates versus prior year period CHF / USD +4.3% CHF / EUR +1.9% CHF / JPY +7.6% Difference in CHF / CER growth Sales growth Q1 2016 vs. Q1 2015 3.9% CER growth +1.0%p 4.9% CHF growth Q1 HY YTD 9 FY CER=Constant Exchange Rates 179

Doing now what patients need next